Embed Size (px)
Citation preview
BioPartnering North America 2009 참가회사 프로필 요약
Company name: 1 AGILE THERAPEUTICS
Website: http://www.agiletherapeutics.com/index.html
Contact Person: Jeffrey Frick, Chief Business Officer, (609) 683-1880, ext 153 NJ USA
Products and Services: Products and Services: Agile Therapeutics (Agile) is a privately held specialty
pharmaceutical company focused on the development of innovative women’s
healthcare products.
Agile’s franchise strategy is to build a pipeline of innovative, women's health
products. The company's lead program is a low-dose, once-weekly contraceptive
patch. To date, the Company has raised a total of $35 million in venture funding.
Partnering meeting 희망여부
Company name: 2 AIM Therapeutics Inc.
Website: http://www.aimtherapeutics.com
Contact Person: MaRS Centre, Heritage Building, 101 College Street, Suite 335
Toronto, Ontario, M5G 1L7, Phone: 416.673.8199, Fax: 416.971.7300,
Products and Services: Products and Services: AIM Therapeutics is engaged in the discovery and
development of breakthrough medical therapies to improve the lives of people
with immune and inflammatory disorders. Originally founded in June 2005 as
AtheroMedix Inc., the company merged with Salpep Biotechnology Inc. in March
2007 to form AIM Therapeutics Inc. The company’s new name stands for
‘Advanced Immune Modulation’ which more accurately represents our
broadened technology platforms. AIM Therapeutics is focused on developing
novel treatments for asthma, COPD, bronchitis, spinal cord injury, restenosis,
type 1 diabetes and other inflammatory conditions with significant unmet medical
needs.
Partnering meeting 희망여부
Company name: 3 Akesis Pharmaceuticals, Inc.
Website: http://www.akesis.com/
Contact Person: 888 Prospect Street, Suite 320 La Jolla, CA 92037, Tel: 1 888 476 5115, Fax: 1
858 348 2183, Email: [email protected]
Products and Services: Products and Services: Akesis Pharmaceuticals is a development stage
company focused on developing and commercializing breakthrough therapeutics
for a broad spectrum of metabolic diseases, including but not limited to diabetes,
obesity, and dyslipidemias. Akesis is well positioned with its lead drug candidate,
1
AKP-020, a unique, patent-protected p vanadium-containing product that has
been shown to lower blood glucose levels in type 2 diabetes patients. The
company also intends to in-license preclinical and clinical stage compounds that
have metabolic disease treatment potential. Akesis’ management team is highly
experienced in drug development and is leading the company in validating these
findings, with the goal of offering unique FDA approved products to treat
diabetes and other metabolic diseases that significantly impact public health.
Partnering meeting 희망여부
Company name: 4 Alder BioPharmaceuticals
Website: http://www.alderbio.com/
Contact Person: 11804 North Creek Parkway South, Bothell, WA 98011. Phone: 425-205-2900
Fax: 425-205-2901. Email: [email protected]
Products and Services: Products and Services: Alder uses its proprietary technologies to uniquely
identify, develop, produce and market its own antibody therapeutics. The work
being done at Alder today will help those who suffer from cancer, autoimmune
diseases, and inflammatory diseases. Alder is revolutionizing the way the
pharmaceutical industry discovers, develops and produces antibody
therapeutics. Through various licensing agreements, Alder has used its
proprietary technology to help major biopharmaceutical partners advance novel
therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy
also includes identifying a strategic partner to assist in the development and
marketing of its lead antibody product, ALD518, for Rheumatoid Arthritis and
Cancer.
Partnering meeting 희망여부
Company name: 5 Allergy Therapeutics plc
Website: http://www.allergytherapeutics.com/
Contact Person: Allergy Therapeutics, Dominion Way, Worthing, West Sussex, BN14 8SA, United
Kingdom. Tel +44 (0)1903 844 700
Products and Services: Products and Services: Allergy Therapeutics®. (AT) is a Europe-based
specialty pharmaceutical company focused upon the diagnosis and treatment of
allergy. AT has an existing sales base of approximately £33.8m/€43m per
annum, an MHRA-approved manufacturing capability and an established sales
and marketing infrastructure in several major European markets. In addition, the
Company has a number of novel compounds which have already undergone
initial clinical evaluation and once registered could potentially revolutionise the
treatment of allergy.
Partnering meeting 희망여부
2
Company name: 6 Alpharma Inc.
Website: http://www.alpharma.com/pages/default.aspx
Contact Person: 440 Route 22 East, Bridgewater, NJ 08807. (908) 566-3800.
Products and Services: Products and Services: Alpharma Inc. (NYSE: ALO) is a global specialty
pharmaceutical company with leadership positions in products for humans and
animals. With nearly 1,400 employees and 2007 revenues of $722 million,
Alpharma is active in more than 80 countries around the world. Founded in
Norway in 1903, Alpharma is currently positioned for growth atop two
strong businesses: pharmaceutical products (KADIAN® capsules and the
FLECTOR® Patch), and animal health . Together, these business units provide
operational efficiencies and enable the company to continue to deliver
sustainable growth and long-term value.
Alpharma has a growing franchise in the U.S. pain market with KADIAN®
capsules and the FLECTOR® Patch. Alpharma is internationally recognized as a
leading provider of pharmaceutical products for poultry and livestock through its
animal-health division.
Partnering meeting 희망여부
Company name: 7 Alphora Research Inc.
Website: http://www.alphoraresearch.com/
Contact Person: 2395 Speakman Drive, Suite 2001, Mississauga, Ontario Canada L5K 1B3
Tel: 905 403 0477. Fax: 905 403 8744. Email: [email protected]
Products and Services: Products and Services: Alphora Research Inc. provides API (Active
Pharmaceutical Ingredient) technology development services for the scale up of
complex small molecules with pharmaceutical and biotechnological applications.
Founded in 2003 by Dr. Jan Oudenes, the company is located in Sheridan
Research Park in Mississauga, Ontario, Canada. The location ideally places the
company within the Pharmaceutical community in Canada and in close proximity
to 5 major universities and their associated resources.
Alphora's range of services cover the developmental requirements for API's from
pre-clinical through to phase III and to the successful technology transfer to
manufacturing locations throughout the world.
Partnering meeting 희망여부
Company name: 8 Ambit Biosciences
Website: http://www.ambitbio.com/
Contact Person: 4215 Sorrento Valley Blvd. San Diego, CA 92121. Tel: 858-334-2100. Fax: 858-
334-2199 email: [email protected].
3
Products and Services: Products and Services: Ambit Biosciences is a privately-held
biopharmaceutical company engaged in the discovery and development of
small-molecule kinase inhibitors for the treatment of cancer.
With more than 500 distinct kinases identified and over 30 kinase inhibitors in
clinical trials or FDA approved, this important class of proteins is a rich area for
therapeutic drug development. And Ambit Biosciences has the technology, the
expertise and the vision to succeed in the kinase space. Ambit Biosciences is
combining the power of their KINOMEscan™ kinase profiling technology with an
innovative licensing strategy and a history of kinase expertise to discover,
optimize and advance a sustainable pipeline of small molecule kinase inhibitors
for the treatment of cancer.
Partnering meeting 희망여부
Company name: 9 Amicus Therapeutics
Website: http://www.amicustherapeutics.com/
Contact Person: 6 Cedar Brook Drive, Cranbury, NJ 08512. Tel 609-662-2000. Fax 609-662-2001
Email: [email protected]
Products and Services: Products and Services: Amicus Therapeutics is a clinical-stage
biopharmaceutical company focused on the discovery, development, and
commercialization of a new class of small molecule, orally-administered drugs to
treat a range of human genetic diseases. Amicus’ innovative therapies apply to
conditions in which crucial proteins are defective as a result of improper folding.
Instead of trying to replace these complex proteins, Amicus’ approach uses
pharmacological chaperones to selectively bind to the misfolded target protein,
increase stability, and help the protein fold into its proper three-dimensional
shape. This allows the protein to be trafficked to the specific location in the cell,
where it performs its intended biological function. Pharmacological chaperone
technology represents a novel, next-generation approach to the management of
human genetic diseases and offers the potential to improve treatment options for
patients.
Partnering meeting 희망여부
Company name: 10 Anapharm
Website: http://www.anapharm.com/
Contact Person: 2500, rue Einstein, Québec (Qc Canada G1P 0A2 Phone: (418) 527-4000
Fax: (418) 527-3456. Email: [email protected]
Products and Services: Products and Services: Anapharm is an industry leader in early-phase drug
development, providing a wide range of services to the pharmaceutical,
biotechnology, and generic-drug industries. Anapharm offers a vast array of
4
bioanalytical laboratory services, as well as services in Phase I clinical
development, bioequivalence, and regulatory affairs.
As a PharmaNet Development Group company, Anapharm has access to a
global network of resources for Phase I–IV consulting and clinical drug
development.
Partnering meeting 희망여부
Company name: 11 Apeiron Biologics
Website: http://www.apeiron-biologics.com/
Contact Person: Forschungs- und Entwicklungs GmbH, Campus Vienna Biocenter 5, 1030
Vienna, Austria. Tel: +43 (1) 865 65 77. Fax:+43 (1) 865 65 77 – 9280. Email:
Products and Services: Products and Services: The company, operational since 2005, was founded by
Josef Penninger, the director of the Institute of Molecular Biotechnology of the
Austrian Academy of Sciences (IMBA). Based on Josef Penninger's research
activities, three projects are currently pursued: APN 01: Development of
recombinant human soluble Angiotensin Converting Enzyme 2 as a therapy for
the Acute Respiratory Distress Syndrome as well as cardiovascular and kidney
diseases. Cbl-b: Shaping of immunoreactivity by molecules inhibiting or
enhancing the function of Cbl-b, a critical negative regulator of T-cell activation
and autoimmunity.
DREAM: Novel approach for pain management by induction of the expression of
the endogeneous opioid precursor prodynorphin via interaction with the
suppressor protein DREAM.
Apeiron's general strategy is to generate value by profiling and developing
therapeutics up to a first proof of concept in patients (Phase I / II clinical trials).
Following successful proof of concept in patients, the aim is to out-license
projects to pharmaceutical companies, enabling the initiation of new R&D
projects.
Partnering meeting 희망여부
Company name: 12 Apthera, Inc.
Website: http://www.apthera.com/
Contact Person: Gail Thurston, Vice President, Corporate Development. Tel: (480) 348-9707
Email: [email protected]
Products and Services: Products and Services: Apthera, Inc. was founded in July, 2005 to develop and
commercialize a pipeline of peptide-based immunotherapies for the adjuvant
treatment of HER2-positive cancers. Currently, the Company has products in
clinical trials aimed at reducing disease recurrence rates for breast and prostate
5
cancers. Apthera licensed its core intellectual property from The University of
Texas M. D. Anderson Cancer Center (MDACC) in Houston, TX, and The Henry
M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) in
Rockville, MD. Apthera recently announced positive Phase I/II clinical trial results
for its lead cancer immunotherapy product, NeuVax™ for the treatment of breast
cancer. Planning is underway for a large, international, pivotal Phase III clinical
trial of NeuVax for the treatment of early-stage (node-positive) HER2-positive
breast cancer. Apthera intends to obtain regulatory approval of NeuVax for the
treatment of breast cancer in both the U.S. and international markets.
Partnering meeting 희망여부
Company name: 13 Aquinox Pharmaceuticals Inc
Website: http://www.aqxpharma.com/
Contact Person: Suite 600 - 555 West 12th Avenue, Vancouver, BC V5Z 3X7 Canada
t: 604.629.9223 Email: [email protected]
Products and Services: Products and Services: Aquinox Pharmaceuticals is a pharmaceutical company
committed to the discovery, development, and commercialization of novel and
targeted small molecule therapeutics for the treatment of cancer and
inflammatory disease.
The company was founded in 2004 as a spin-off from research conducted at the
University of British Columbia, the BC Cancer Agency and the Vancouver
Coastal Health Research Institute, organizations with outstanding reputations for
world-class research. The scientific founders of the company discovered a
unique biochemical enzyme called SH2-containing inositol 5'-phosphatase
(known as SHIP) and drugs to regulate this enzyme. Activation of SHIP inhibits
the critical PI3K pathway in blood cells. The PI3K pathway promotes cell growth,
proliferation, survival, and immune cell activation.
Aquinox's most advanced program is its SHIP activator program and has
generated promising data with the highly selective compound AQX-MN100, a
potent activator of SHIP. AQX-MN100 possesses many desirable drug properties
and has demonstrated potent anti-cancer activity as well as anti-inflammatory
activity both in vitro and in vivo. Aquinox is now evaluating AQX-MN100, and
several closely related analogs that have properties for different routes of
administration, and is poised to complete final preclinical testing and advance its
lead product into IND studies.
The company's second program is its SHIP inhibition program for blood cell
recovery and is making advances in developing drug candidates.
Partnering meeting 희망여부
6
Company name: 14 ARIUS Research Inc.
Website: http://www.ariusresearch.com/
Contact Person: 55 York Street, 15th Floor, Toronto, Ontario M5J 1R7. T 416 862 2323. F 416
862 9696. E [email protected]
Products and Services: Products and Services: ARIUS is a biotechnology company discovering and
developing the next wave of antibody therapeutics to treat cancer and other
diseases. At the core of the Company is our unique, proprietary
FunctionFIRST™ technology platform that generates and selects therapeutic
antibodies based on their activity. This antibody generation engine has enabled
ARIUS to grow a pipeline of more than 400 antibody drug candidates. In addition
to the antibodies we are developing in-house, ARIUS has ongoing partnerships
with key biotechnology and drug development companies.
Partnering meeting 희망여부
Company name: 15 Asterand plc
Website: http://www.asterand.com/Asterand/
Contact Person: TechOne Suite 501, 440 Burroughs, Detroit, MI 48202-3420 United States.
Tel: + 1 (313) 263-0960. Fax: +1 (313) 263.0961. Email:
Products and Services: Products and Services: Asterand plc is the leading global supplier of high
quality, well characterized human tissue and human tissue-based research
services to drug discovery scientists. Our mission is to provide human tissues
and services to accelerate the identification and validation of drug targets and
enhance the selection of drug candidates with an increased likelihood of clinical
success.
Formed in January 2006 from the merger of Asterand, a human tissue
biorepository, and Pharmagene, a human tissue-based drug discovery company,
The company is uniquely positioned to provide a comprehensive approach to
meet the research needs of pharmaceutical and biotechnology companies.
F ocused on providing services and products to accelerate drug discovery
research from target identification through to compound evaluation and drug
safety.
Partnering meeting 희망여부
Company name: 16 AstraZeneca
Website: http://www.astrazeneca.ca/
Contact Person: 1004 Middlegate Road, Mississauga, Ontario Canada L4Y 1M4. Tel: (905) 277-
7111 or 1-800-565-5877. Fax: (905) 270-3248. Email:
7
Products and Services: Products and Services: AstraZeneca is one of the largest pharmaceutical
companies in the world. Their innovative and extensive product portfolio spans
six therapeutic areas: cardiovascular, gastrointestinal, oncology, respiratory,
neuroscience and infection.
Partnering meeting 희망여부
Company name: 17 Avance
Website: N/A
Contact Person: N/A
Products and Services: N/A
Partnering meeting 희망여부
Company name: 18 Avantium Technologies B.V.
Website: http://www.avantium.com/
Contact Person: Zekerringstraat 29, 1014 BV Amsterdam, The Nertherlands. Tel: +31
(0)20 586 8080. Fax: +31 (0)20 586 8085. Email: [email protected]
Products and Services: Products and Services: Avantium is a leading technology company specialized
in advanced high-throughput R&D for application in the energy, chemicals and
pharmaceutical industries. The company’s headquarters and laboratories are
located in Amsterdam, in the Nertherlands. Avantium’s proprietary high-
throughput technology enables a faster and more cost-effective development of
new and improved products and production processes. Using its unique rational
approach towards the design of experiments and data analysis, Avantium has
demonstrated the validity and commercial viability of its technology by
successfully providing research services and tools to more than 70 companies
worldwide, including many industry leaders. The company’s mission is to
increase the success rate and economics of product and process development.
Partnering meeting 희망여부
Company name: 19 Bachem AG
Website: http://www.bachem.com/
Contact Person: 3132 Kashiwa Street Torrance, CA 90505 United States Phone +1 888 422 2436
Fax: +1 310 539 9428
Products and Services: Products and Services: Bachem is an independent, technology-based, public
biochemicals company providing full service to the pharma and biotech industry.
Bachem is specialized in the process development and the manufacturing of
peptides and complex organic molecules as active pharmaceutical ingredients
(APIs), as well as innovative biochemicals for research purposes. With
headquarters in Bubendorf, Switzerland, and affiliates in Europe and the US,
8
Bachem works on a global scale and holds a leading position in the field of
peptides
Partnering meeting 희망여부
Company name: 20 Bayer AG
Website: http://www.bayer.com/en/homepage.aspx
Contact Person: 51368 Leverkusen. Tel: ++49 (0)214 / 30-1
Products and Services: Products and Services: Bayer is a global enterprise with core competencies in
the fields of health care, nutrition and high-tech materials. Bayer AG defines
common values, goals and strategies for the entire Group. The three subgroups
and three service companies operate independently, led by the management
holding company. The Bayer Group markets some 5,000 products. Best-sellers
include: in the health care field: Yasmin®/YAZ®/Yasminelle®,
Betaferon®/Betaseron®, Kogenate®, Adalat®, Avalox®/Avelox®
Nutrition field: Confidor®/Gaucho®/Admire®/Merit®, Flint®/Stratego®/Sphere®
High-tech materials field: Makrolon®, Baydur®, Bayflex® Footwear.
Partnering meeting 희망여부
Company name: 21 Bend Research
Website: http://www.bendres.com/
Contact Person: Bruce Johnson, Manager, Business Development. Tel: 541-382-4100. Email:
Products and Services: Products and Services: Bend Research’s core business is the development of
new technologies for the pharmaceutical industry. They began operations in
Central Oregon in 1975 and, since that time, have focused on applying
fundamental scientific and engineering principles to provide enabling, proprietary
technologies to address our clients' needs.
Partnering meeting 희망여부
Company name: 22 BioAlberta
Website: http://www.bioalberta.com/index.asp
Contact Person: 314 Capital Place, 9707-110 Street, Edmonton, AB T5K 2L9 Tel: (780) 425-3804
Fax: (780) 409-9263 Email: [email protected]
Products and Services: Products and Services: BioAlberta is the central voice and the organizing hub
for the bioindustry in Alberta, Canada. BioAlberta is a private, not-for-profit
industry association, representing Alberta's growing bioindustry. BioAlberta
currently lists over 130 members, including producers, users and supporters of
biotechnology activities in Alberta.
BioAlberta activities are focused in the following areas: Government advocacy,
9
Industry promotion, Increasing industry access to financing, Facilitating access
to human resources and Business development and networking opportunities.
Alberta's bioindustry is a broad field of endeavour encompassing biotechnology,
environmental science, medical technology, industrial bioproducts, agriculture
biotechnology, bio-informatics and natural health products.
Partnering meeting 희망여부
Company name: 23 Biolex Therapeutics
Website: http://www.biolex.com/
Contact Person: 158 Credle Street, Pittsboro, NC 27312 USA. Tel: 919.542.9901. Fax:
919.542.9910. Email: [email protected]
Products and Services: Products and Services: Biolex is a clinical-stage biopharmaceutical company
that uses their patented LEX SystemSM to develop hard-to-make therapeutic
proteins and monoclonal antibodies that have been optimized to enhance their
efficacy and potency. The LEX System is a novel technology that genetically
transforms the aquatic plant Lemna to enable the production of biologic product
candidates. Their lead product candidate, Locteron, is in Phase 2 clinical trials
and is the only controlled-release interferon alfa known to us to be currently in
active clinical development for the treatment of chronic hepatitis C.
Partnering meeting 희망여부
Company name: 24 Bionor Immuno AS
Website: http://www.bionorimmuno.com/
Contact Person: Klostergata 33, NO-3732 Skien, Norway, Tel: +47 35 90 85 00. Fax: +47 35 90
85 01. E-mail: [email protected]
Products and Services: Products and Services: Bionor Immuno AS was established on July 14th 2000
as a spin off from its sister company, Bionor AS (now Bionor Laboratories AS)
that develops peptide-based diagnostics for infectious diseases. Both companies
are located at Klosterøya in Skien, Norway together with Bionor Immuno’s
development partner Mericon AS.
Partnering meeting 희망여부
Company name: 25 Bionovo
Website: http://www.bionovo.com/
Contact Person: 5858 Horton Street, Suite 375, Emeryville, CA 94608. Tel: 510-601-2000. Fax:
510-601-5050
Products and Services: Products and Services: Bionovo is a drug discovery and development
company focused on developing safe and effective drugs for the treatment of
unmet medical needs in women’s health and cancer. Their mission is to improve
10
the quality of women’s health and defeat life-threatening cancers.
Partnering meeting 희망여부
Company name: 26 BioWisdom Ltd
Website: http://www.biowisdom.com/
Contact Person: Harston Mill, Harston, Cambridge CB22 7GG United Kingdom. Tel: +44 (0)1223
874800. Fax: +44 (0)1223 874801. Tel: 1-978-461-1250. Fax: 1-978-461-1299.
Email: [email protected]
Products and Services: Products and Services: BioWisdom develops ontology powered intelligence
solutions for the healthcare industry. Their solutions make extensive use of
medical labels in all of their forms. From text strings to chemical structures these
labels, and the rules that govern the behaviour of the real things behind them,
are used to power our technology. Search can be enlightened and results
clustered. Information can be annotated and filtered. Data can be formatted and
‘semantically' normalized. Intelligence can be visualized and interrogated.
All of BioWisdom's products and services are focused on access, formatting and
visualization of healthcare intelligence providing unparalleled cognitive reach for
individuals, teams and organisations
Partnering meeting 희망여부
Company name: 27 Burrill & Company
Website: http://www.burrillandco.com/
Contact Person: One Embarcadero Canter Suite 2700, San Francisco, CA 94111. Tel: 415-591-
5400. Fax: 415-591-5401. Email: [email protected]
Products and Services: Products and Services: Burrill & Company is a life sciences merchant bank
focused exclusively on companies involved in biotechnology, pharmaceuticals,
diagnostics, devices, human healthcare and related medical technologies,
nutraceuticals and wellness, agricultural biotechnology, and industrial
biotechnology (biomaterials/bioprocesses) with over $950 million under
management.
Burrill's technical and venture investing competence spans the entire spectrum
of life sciences. The expertise of the firm's investment team, strategic partners
and Advisory Boards is unparalleled in depth and breadth. In addition, Burrill is a
leader in life science strategic partnering, an invaluable practice to build value in
portfolio companies and to accelerate their growth and development.
Partnering meeting 희망여부
Company name: 28 Calibrant Biosystems, Inc
Website: http://www.calibrant.com/
11
Contact Person: 910 Clopper Road, Suite 220N Gaithersburg, MD 20878. Tel: (301) 977-7900.
Fax (301) 977-7981. Email: [email protected]
Products and Services: Products and Services: Calibrant Biosystems, Inc. is a Gaithersburg, Maryland
biotechnology company pioneering the discovery of novel protein drug targets
and markers for the treatment and diagnosis of disease. Calibrant’s unique
approach to protein biomarker discovery applies the proprietary Gemini™
platform to the analysis of microdissected tissue specimens, enabling targeted
and comprehensive evaluation of proteins within isolated cells and their local
microenvironment.
Partners : 1) Leading clinical researchers to develop new first-in-class
therapeutics, beginning with the discovery of novel protein drug targets, disease
pathways, and biomarkers from microdissected human tissue specimens. With
an initial focus in oncology, Calibrant researchers have active development
programs in a range of cancer indications including ovarian and primary brain
cancer.
2) Pharmaceutical and biotechnology companies seeking to leverage the
Gemini™ engine during the drug development process by identifying novel
therapeutic targets, reducing drug development times and attrition rates, and
developing targeted drugs or repositioning existing compounds on the basis of
effective patient stratification.
Partnering meeting 희망여부
Company name: 29 Catalent Pharma Solutions, Inc. /Gala Biotech
Website: http://www.gala.com/index.html
Contact Person: 8137 Forsythia Street, PO Box 620160 Middleton, WI 53562. Phone:
608.824.9920. Fax: 608.824.9930. Email: [email protected]
Products and Services: Products and Services: Gala Biotech, a Catalent Pharma Solutions Company,
was established in 1996 from technology developed at the University of
Wisconsin. Located in Middleton, Wisconsin, this rapidly growing company
(currently over 40 employees, including 16 PhD’s) has a wide range of
capabilities in the fields of molecular biology, vector biology, cell line
development, biopharmaceutical manufacturing, protein biochemistry, and
quality systems. Gala’s core proprietary technology is GPEx® (Gene Product
Expression), a gene insertion/expression technology that allows rapid creation of
stable, high-expressing mammalian cell lines for a wide variety of gene products.
Partnering meeting 희망여부
Company name: 30 Ceapro Inc.
Website: http://www.ceapro.com
12
Contact Person: Suite 4174 Enterprise Square, 10230 Jasper Avenue, Edmonton, Alberta,
Canada T5J 4P6. Tel: 780.421.4555. Fax: 780.421.1320. Email:
Products and Services: Products and Services: Incorporated in 1997, Ceapro's mission is to be a
global leader in developing and commercializing products for the human and
animal health market through the use of proprietary technology and renewable
resources.
Ceapro has achieved a reputation as an innovative formulator and advanced
processor of active ingredients, botanical extracts, and therapeutic products.
They take the best nature has to offer and create ingredients and formulations
that lead to the development of effective shampoos, cleansers, moisturizers, and
cosmetics - licensed and marketed worldwide.
Partnering meeting 희망여부
Company name: 31 Cellzome AG
Website: http://www.cellzome.com/index.html
Contact Person: Cellzome in Germany, Ms. Hilary Soul, Cellzome AG Meyerhofstrasse 1
69117 Heidelberg, Germany. Tel. +49 (0) 6221 137 57 0. Fax. +49 (0) 6221 137
57 201. Email: [email protected]
Products and Services: Products and Services: Cellzome is a privately-owned drug discovery company
identifying a new generation of kinase- targeted drugs to treat inflammatory
diseases.
P ipeline of small-molecule therapeutics is driven by Kinobeads™, a proprietary
technology for the screening and profiling of kinases in relevant cells and
tissues.
Cellzome is applying its distinctive Kinobeads™ technology to the discovery and
development of novel, selective, kinase inhibitors targeting key inflammatory
mediators in immune receptor signalling and chemotaxis, including PI3Kγ and
Zap-70.
Partnering meeting 희망여부
Company name: 32 Circassia
Website: http://www.circassia.co.uk/
Contact Person: Magdalen Centre, The Oxford Science Park, Oxford OX4 4GA UK. Tel: +44
(0)1865 784574. Fax: +44 (0)1865 784576. All business development
opportunities should be directed to Charles Swingland: Email:
Products and Services: Products and Services: Circassia is a clinical-stage specialty
13
biopharmaceutical company focused on developing medicines designed to cure
allergies, combat organ transplant rejection and speed recovery after major
surgery.
The Company was initially founded to develop and commercialise a range of
allergy therapeutics, based on its proprietary technology, which have the
potential to transform current treatment. With its portfolio of allergy products
progressing through clinical development, the company has broadened its
pipeline into other areas where immune system control is essential. The first of
these is organ transplant rejection. Circassia is also developing a critical care
therapy that is designed to improve patients’ recovery after a range of surgical
operations.The Company is well funded having completed a first round fund
raising in January 2007 and a second round in January 2008, and is supported
by a syndicate of widely respected institutional and venture capital investors.
Partnering meeting 희망여부
Company name: 33 CIRION BioPharma Research Inc.
Website: http://www.cirion.com/
Contact Person: 2121 Berlier, Laval, QC H7L 3M9. Tel: 450-682-2231. Fax: 450-902-3060.
Email: [email protected]
Products and Services: Products and Services: CIRION was founded by Dr. Sylvain Desrochers and
Dr. Lise Dallaire, high-level researchers with a passion for innovation and
research excellence. CIRION now is a leading provider of global central
laboratory services and is proud to count some of the world's top 10
biopharmaceutical companies among its clients. CIRION is a knowledge-based,
GLP-compliant Central Laboratory dedicated to providing project management
services and scientific expertise for Phase I to IV clinical studies. CIRION has
developed expertise in the management of complex clinical research projects.
Partnering meeting 희망여부
Company name: 34 CoMentis, Inc.
Website: http://www.comentis.com/
Contact Person: 280 Utah Avenue, Suite 275, South San Francisco, CA 94080. Phone: 650-869-
7600. Fax: 650-869-7626. Email: [email protected]
Products and Services: Products and Services: CoMentis, Inc. is headquartered in South San
Francisco, with research operations in both South San Francisco and Oklahoma
City. The company is engaged in the discovery and development of small-
molecule drugs to treat Alzheimer’s disease, age-related macular degeneration
(AMD) and cognitive disorders.
The company has two fundamental technology platforms: (i) aspartic protease
14
inhibitors, including beta-secretase inhibitors for Alzheimer’s disease; and (ii)
nicotinic acetylcholine receptor (nAChR) agonists and antagonists for the
treatment of angiogenesis mediated diseases and cognitive disorders.
CoMentis currently has three product development programs in its pipeline: ATG-
3, a topical (eye drop) anti-angiogenesis compound for neovascular AMD in
Phase II development; CTS-21166, an orally active beta-secretase inhibitor for
Alzheimer’s disease in Phase I development; and a series of next generation α7
nAChR agonists in preclinical development.
Partnering meeting 희망여부
Company name: 35 Conformetrix
Website: http://www.conformetrix.com/index.html
Contact Person: Dr. Gordon Barker, Business Development Manager. The Manchester Incubator
Building, 48 Grafton Street, Manchester, M13 9XX, UK. Email:
[email protected] T:+44-(0)161-606-7213. F:+44-(0)161-606-7300.
Products and Services: Products and Services: Conformetrix offers a new platform technology that, for
the first time, can rapidly determine highly accurate and biologically-relevant
(aqueous) 3D and 4D structures of any small soluble molecule. Uniquely, our
proprietary method quantifies experimentally the 4D conformational preference
(in terms of modality, angle and libration amplitude) of each rotatable bond
without recourse to electrostatics or van der Waals calculations.
Partnering meeting 희망여부
Company name: 36 Corealis Pharma Inc.
Website: http://www.corealispharma.com/
Contact Person: 141, Avenue du Président-Kennedy, Suite SB – 6520 Montréal (Québec)
Canada H2X 3Y7 Tel : (514) 987 – 0401. Fax : (514) 987 – 0432. Email:
Products and Services: Products and Services: COREALIS Pharma is dedicated to the research and
development of pharmaceutical finished solid dosage forms through the use of
robust and innovative formulation and process technologies in order to surpass
the specific needs of the pharmaceutical industry of today and tomorrow.
Partnering meeting 희망여부
Company name: 37 Critical Pharmaceuticals Ltd
Website: http://www.criticalpharmaceuticals.com
Contact Person: Gareth King, PhD. Chief Business Officer. BioCity Nottingham, Pennyfoot
Street, Nottingham, NG1 1GF, United Kingdom. Tel: +44 (0)115 8820 100. E-
mail: [email protected]
15
Products and Services: Products and Services: Critical Pharmaceuticals is a biotechnology company
with proprietary drug delivery technologies for injectable sustained release and
nasal delivery of challenging drugs including proteins and peptides. Critical
Pharmaceuticals are experts in drug delivery and are developing a number of
ground breaking products to treat diseases as diverse as growth hormone
deficiency and schizophrenia.
Critical Pharmaceuticals actively partners its drug delivery technologies and
candidate drugs with pharmaceutical and biotechnology companies. For more
information, or to discuss a specific opportunity, please contact us.
Partnering meeting 희망여부
Company name: 38 CSL Limited
Website: N/A
Contact Person: Zita Cunningham, Vice President Business Development. Phone: +61 3 9389
1824. Email: [email protected] address: 45 Poplar Rd, Parkville, Victoria
3052 Australia.
Products and Services: Products and Services: The CSL Group has a combined heritage of
outstanding contribution to medicine and human health with more than 90 years
experience in the development and manufacture of vaccines and plasma protein
biotherapies. They develop and manufacture vaccines and plasma protein
biotherapies. These products help treat and prevent serious human medical
conditions
With major facilities in Australia, Germany, Switzerland and the US, CSL has
over 9000 employees working in 27 countries.
Partnering meeting 희망여부
Company name: 39 CTI Life Sciences Fund
Website: http://www.ctisciences.com/english/
Contact Person: Richard J. Meadows, Managing Partner, CTI Life Sciences Fund. 1, Place Ville-
Marie, office #1635 Montreal, Quebec, Canada H3B 2B6. Phone: (514) 787-
1618. Cell: (514) 826-8326. Fax: (514) 787-1620.
E-mail:
Products and Services: Products and Services: Based in Montreal, CTI Life Sciences Fund L.P. is a
limited partnership formed in 2006. The Fund make venture capital investments
in high quality emerging life sciences companies at the start-up and clinical
development stage primarily in Canada. This fund is the first of its kind created in
Quebec since 2002.
CTI Life Sciences Fund L.P. has secured C$100 million in commitments from
Quebec, institutional investors such as the Caisse de dépôt et placement du
16
Québec, the Solidarity Fund QFL, FIER Partners L.P. and the Régime de rentes
du Mouvement Desjardins and CTI Capital Group’s partners.
The CTI Life Sciences Fund L.P. team of professionals in science and finance
has extensive experience in the biotechnology and the pharmaceutical
industries. The Fund works closely with entrepreneurs and researchers to
increase the value of these young companies.
Partnering meeting 희망여부
Company name: 40 Curis, Inc
Website: http://www.curis.com/index.php
Contact Person: 45 Moulton Street, Cambridge, MA 02138. Tel: [617] 503-6500. Fax: [617] 503-
6501.
Products and Services: Products and Services: Curis is a drug development company that is
committed to leveraging its innovative signaling pathway drug technologies to
seek to create new targeted small molecule drug candidates for cancer. In
expanding its drug development efforts in the field of cancer through its
proprietary targeted cancer programs, Curis is building upon its previous
experiences in targeting signaling pathways for the development of next
generation targeted cancer therapies.
Partnering meeting 희망여부
Company name: 41 Cytokinetics, Inc.
Website: http://www.cytokinetics.com/
Contact Person: 280 East Grand Avenue, South San Francisco, CA 94080. Tel:(650) 624-3000.
Fax: (650) 624-3010. Email: [email protected]
Products and Services: Products and Services: Cytokinetics is a different kind of company. It is
increasingly unusual that an emerging growth biotechnology company would be
dedicated to the discovery, development and commercialization of therapeutics.
Similarly, it is more and more uncommon for a biopharmaceutical company to
tackle the pursuit of new treatments for multiple disease areas, including cancer
and cardiovascular diseases. However, the most important distinguishing feature
of Cytokinetics is instead found in their commitment to innovation that has
translated their focus on the cytoskeleton into a Research and Development
pipeline of multiple, first-in-class compounds. All of the programs they are
pursuing offer entirely novel therapeutic approaches to severe unmet clinical
needs.
Partnering meeting 희망여부
Company name: 42 Cytovance Biologics, Inc.
17
Website: http://www.cytovance.com/
Contact Person: 840 Research Parkway, Suite 400, Oklahoma City, OK 73104. Phone: (405) 319-
8310. Fax: (405) 319-8339. Email: [email protected]
Products and Services: Products and Services: Cytovance Biologics® was founded to help
biopharmaceutical companies move recombinant protein and antibody products
rapidly from the bench through clinical development.
Their unique services couple first-hand client-side experience with technical
expertise and operational excellence to efficiently and cost-effectively deliver
processes, products and the supporting knowledge necessary to complete
clinical development and meet regulatory requirements.
They offer a comprehensive range of process development and cGMP
manufacturing services conducted in brand new state-of-the-art facilities, plus a
portfolio of technical, financial and strategic support services.
Partnering meeting 희망여부
Company name: 43 KAI Pharmaceuticals Inc.
Website: http://www.kaipharma.com/
Contact Person: Natalie Holles, Vice President, Business Development. Email:
[email protected] Address: 270 Littlefield Avenue, South San
Francisco, CA 94080. Tel: (650) 244-1100
Products and Services: Products and Services: KAI (kī) Pharmaceuticals is a drug discovery and
development company with multiple, novel clinical-stage programs in
cardiovascular disease and pain.
Lead product candidate : KAI-9803, is partnered with Bristol-Myers Squibb and
has demonstrated efficacy in reducing damage to heart muscle and improving
cardiac function in patients with myocardial infarction (MI) who undergo balloon
angioplasty.
S econd clinical program : KAI-1678, is a promising first-in-class drug candidate
that may address both the inflammatory and neuropathic pain markets.
T hird clinical program : KAI-1455, is designed to reduce ischemic injury during
planned surgical procedures, such as coronary artery bypass grafting, vascular
surgery and pediatric cardiac surgery.
KAI’s expertise is in the selective modulation of intracellular protein:protein
interactions via delivery of peptide drugs into the cell. The Company has applied
its core technology to discover highly potent and selective inhibitors and
18
activators for validated members of the protein kinase C (PKC) family of
isozymes. This approach has demonstrated therapeutic potential clinically and in
many preclinical disease models
Partnering meeting 희망여부
Company name: 44 JERINI AG
Website: http://www.jerini.com/cms/en/home.php
Contact Person: Jerini AG Invalidenstrasse, 130 10115 Berlin Germany. T +49-30-978 93-0
F +49-30-978 93-105. Email: [email protected]
Products and Services: Products and Services: Jerini is a pharmaceutical company focusing on the
discovery, development, and commercialization of novel peptide-based drugs.
The company pursues disease indications that have limited or no treatment
options and has built a drug pipeline composed of its own programs, as well as
others in collaboration with partners.
Partnering meeting 희망여부
Company name: 45 Intas Biopharmaceuticals Ltd
Website: http://www.intasbiopharma.co.in/
Contact Person: Plot No. 423 / P / A/ GIDC, Sarkhej - Bavla Highway, Moraiya, Taluka - Sanand,
382 210. Ahmedabad, Gujarat, India. Tel: +91 - 2717 - 660100/01. Fax : +91 -
2717 – 251189. Email: [email protected]
Products and Services: Products and Services: Intas Biopharmaceuticals, Ltd. develops and markets
biopharmaceutical products. Its products include rHu G-CSF that is used
clinically for prevention and treatment of chemotherapy-induced neutropenia;
and rHu EPO, which is used clinically for prevention and treatment of
chemotherapy-induced neutropenia and renal failure. The company also offers
oncology products, such as Cytax, Gemibine, Carbopa, Zodox, and Bical;
Redemide, Arsenox, Arasid, Dabaz, Merex, Hyras, and Intalfa; and Neukine,
Zolasta, Itaspor, and Clogen. In addition, Intas Biopharmaceuticals provides
contract research and manufacturing services for bulk biopharmaceuticals and
finished formulations.
Partnering meeting 희망여부
Company name: 46 Inovio Biomedical Corp.
Website: http://www.genetronics.com/
Contact Person: Dr. Michael Fons, Vice-President, Corporate Development. Phone: 858-410-
3122. Address: Corporate Headquarters, Inovio Biomedical Corporation, 11494
19
Sorrento Valley Rd. San Diego, CA USA 92121-1318. Phone: 858-597-6006.
Fax: 858-597-0451
Products and Services: Products and Services: Inovio Biomedical Corporation (AMEX: INO) is focused
on the development of next-generation vaccines to prevent or treat cancers and
chronic infectious diseases. Successful development of this new generation of
vaccines — DNA vaccines — has been hindered by the lack of safe, efficient and
cost effective DNA delivery methods capable of enabling their potency. Inovio's
electroporation-based DNA delivery technology has shown potential to play a
pivotal role in facilitating delivery and enhancing the potency of preventive and
therapeutic vaccines.
Inovio is a leader in developing DNA delivery solutions based on electroporation ,
which uses brief, controlled electrical pulses to create temporary pores in cell
membranes and enable dramatically increased cellular uptake of a useful
biopharmaceutical. Once the DNA vaccine enters a cell, it can then "express" the
proteins it was encoded to produce. These proteins, or antigens, are designed to
be uniquely associated with a targeted cancer or infectious disease, and may
then stimulate a more powerful immune response if the immune system
encounters the targeted disease at a subsequent time.
Partners : T argeting diseases with significant unmet treatment needs, including
cancers and chronic infectious diseases such as HIV and hepatitis C virus,
creating products combining DNA-based immunotherapies or DNA vaccines with
Inovio's delivery platform.
Partnering meeting 희망여부
Company name: 47 InNexus Biotechnology Inc.
Website: http://www.ixsbio.com/about.html
Contact Person: Kathy Flint, Tel: (480) 862-7500. Address: 1055 West Hastings Street, Ste 2200
Vancouver, British Columbia Canada V6E 2E9. Tel:1-480-862-7500.
Products and Services: Products and Services: Antibodies and Monoclonal Antibodies Antibodies are
produced naturally within the body and attack (bind with) diseased cells and
either weaken or destroy them, allowing a person to recover from an infection.
Monoclonal Antibody technology allows one to isolate and expand individual
antibodies for the treatment of numerous diseases, including Cancer.
Monoclonal Antibodies display qualities unlike any other drug yet discovered in
that they are very specific (good at targeting ) and relatively non toxic; however,
of the thousands of monoclonal antibodies developed to date only a relative few
have been approved by the FDA as drugs. Most have failed to become approved
drugs because of a lack of potency.
20
InNexus Dynamic Cross Linking (DXL™) Antibody Platform is a drug
modification approach that adds secondary properties to monoclonal antibodies
(binding is a primary property) and applies to virtually every antibody product
currently in development. Adding these secondary properties can increase the
potency of antibodies or add new properties.
As an example, InNexus utilized DXL™ with a humanized monoclonal antibody,
licensed by the FDA for the treatment of non-Hodgkin’s, B-Cell lymphoma.
DXL™ greatly enhanced the killing of cancer cells in culture by this antibody,
dramatically increasing its potential potency.
Partnering meeting 희망여부
Company name: 48 Innate Pharma
Website: http://www.innate-pharma.com/major.html
Contact Person: Grand Pre 121 Ancien Chemin De Cassis Marseille, 13009 France. Phone: 33 4
96 19 05 58.
Products and Services: Products and Services: Now in clinical phase, Innate Pharma is developing
three product platforms that target three classes of innate immune receptors: Tγδ
and NK cell receptors known as receptors of "non-conventional lymphocytes",
and Toll family receptors, expressed by dendritic cells and, for part of them, by
certain classes of cancer cells. Each platform benefits from either direct or
indirect validation of efficacy in various clinical settings, confirming the potential
of this approach developed by Innate Pharma.
Partnering meeting 희망여부
Company name: 49 Inimex Pharmaceuticals, Inc.
Website: http://www.inimexpharma.com/
Contact Person: Inimex Pharmaceuticals Inc. 8540 Baxter Place Burnaby, B.C. Canada V5A
4T8. Tel: (604) 225-2251. Fax: (604) 225-2257. Email: [email protected]
Products and Services: Products and Services: Inimex Pharmaceuticals, Inc. is focused on the
development and commercialization of Innate Defense Regulators (IDRs), novel
first in class drugs that selectively trigger the body’s innate defenses without
causing inflammation.
IDR products have major market potential for infectious disease, cancer, and
inflammatory disease. These products will significantly reduce morbidity and
mortality in the rapidly growing population of immune suppressed and elderly
patients who are "at-risk" for these disorders. IDR products will also benefit
healthcare payors by reducing costs associated with hospitalization. (1) IDR
product IMX942) targets a broad spectrum of life-threatening hospital infections,
21
many of which are caused by antibiotic-resistant bacteria such as methicillin-
resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus
(VRE). IMX942 is active against both normal and drug-resistant bacteria and its
ability to stimulate host innate immune defenses is not susceptible to bacterial
antibiotic resistance mechanisms. The first clinical indication for IMX942 will be
the prevention of infections associated with cancer chemotherapy-induced
immune suppression.
(2) IDR product candidates will be developed for distinct disease areas, with an
emphasis on inflammatory disease and demonstration of the potential for orally
available IDR dosage forms.
The scientific background on IDR-1, a prototype IDR compound, was recently
published in the journal Nature Biotechnology (Nat. Biotech. Vol. 25 No. 4)
Partnering meeting 희망여부
Company name: 50 ImmunoVaccine Technologies Inc.
Website: http://www.immunovaccine.com/
Contact Person: 1819 Granville Street, Suite 303 Halifax, Nova Scotia, B3J 3R1. Tel: (902) 492-
1819. Fax (902) 492-0888. Email: [email protected]
Products and Services: Products and Services: ImmunoVaccine Technologies Inc. (IVT) is a clinical
stage private biotechnology company developing therapeutic cancer and
prophylactic infectious disease vaccines for human health. IVT is
commercializing breakthrough vaccines developed through the combination of
the VacciMax® platform, a vaccine delivery and enhancement system and a
large selection of validated vaccine antigens.
The VacciMax® platform is able to stimulate an earlier, more powerful, long
lasting antibody and cellular immune response. IVT is also able to reduce the
number of doses required for protection against infectious diseases like
influenza. IVT has completed the scale-up and manufacturing method
development for the VacciMax® platform. The company is conducting a Phase 1
clinical trial of IMT 1012, a therapeutic breast and ovarian cancer vaccine and is
planning to begin a second Phase 1 for a therapeutic prostate cancer vaccine in
early 2009.
Partnering meeting 희망여부
Company name: 51 iCo Therapeutics Inc.
Website: http://www.icotherapeutics.com/
Contact Person: John G. Clement Ph.D. Chief Technical officer, Chief Development Officer
777 Hornby Street Vancouver, British Columbia V6Z 1S4 Canada. Phone: 604-
22
602-9414
Products and Services: Products and Services: iCo Therapeutics, Inc., a development stage specialty
pharmaceutical company, focuses on reprofiling and repositioning of drugs and
drug candidates with a previous clinical history for new disease indications. It
has three compounds under development, including iCo-007, an anti-sense
molecule, which is in Phase I clinical trial for diabetic macular edema; iCo-008, a
monoclonal antibody to take into a Phase II clinical trial for allergic conjunctivitis;
and iCo-009, an experimental oral formulation of Amphotericin B, which is at a
pre-clinical stage.
Partnering meeting 희망여부
Company name: 52 Farris, Vaughan, Wills & Murphy Barristers
Website: http://www.farris.com/default.aspx
Contact Person: 25th Floor 700 W Georgia Street, Vancouver, BC Canada V7Y 1B3. Tel: 604 684
9151. Fax: 604 661 9349. Email: [email protected]
Products and Services: Products and Services: Farris is a leading Canadian law firm with offices in
Vancouver, Kelowna and Victoria, British Columbia. For over 100 years, Farris
has provided innovative & practical solutions, timely and efficient service and a
breadth and depth of knowledge and experience in all areas of the law to a
diverse client base including some of the largest public institutions and private
corporations.
Many of our lawyers have been recognized as leaders in their field. A number of
our practitioners are acknowledged in the Canadian Legal Lexpert Directory and
many are ranked among the top 500 leading lawyers in Canada. In addition, we
are the top corporate and litigation law firm in Vancouver, according to Lexpert.
We offer a complete range of legal services including corporate and commercial;
securities; banking; real estate; technology; biotechnology; litigation and labour
law.
Partnering meeting 희망여부
Company name: 53 Solicitors
Website: N/A
Contact Person: [email protected]
Products and Services: Products and Services: Solocitor is a world-wide law firm and offers variety of
legal services
Partnering meeting 희망여부
Company name: 54 Halozyme Therapeutics, Inc.
23
Website: http://www.halozyme.com/
Contact Person: 11388 Sorrento Valley Road, San Diego, CA 92121. Phone: 858.794.8889 Fax:
858.704.8311. Email: [email protected]
Products and Services: Products and Services: Halozyme is a biopharmaceutical company developing
and commercializing products targeting the extracellular matrix for the drug
delivery, oncology, and dermatology markets. The company's portfolio of
products is based on intellectual property covering the family of human enzymes
known as hyaluronidases.
The company's Enhanze Technology is a novel drug delivery platform designed
to increase the absorption and dispersion of biologics. Its first partnership is with
Roche to apply Enhanze Technology to Roche's biological therapeutic
compounds for up to 13 targets. In addition, the company has received FDA
approval for two products: Cumulase® and HYLENEX, for use as an adjuvant to
increase the absorption and dispersion of other injected drugs and fluids.
HYLENEX is partnered with Baxter Healthcare Corporation. The Company also
has a number of different enzymes in its portfolio that are targeting significant
areas of unmet need.
Partnering meeting 희망여부
Company name: 55 Genome British Columbia
Website: http://www.genomebc.ca/aboutus/default.htm
Contact Person: 500-555 West 8th Avenue, Vancouver, BC V5Z 1C6 Phone: (604) 738-8072
Products and Services: Products and Services: Genome British Columbia is a research organization
that invests in and manages large-scale genomics and proteomics research
projects and science and technology platforms focused on areas of strategic
importance such as human health, forestry, fisheries, ethics, agriculture and the
environment. By working collaboratively with all levels of government,
universities and industry, Genome BC is the catalyst for a vibrant, genomics-
driven life sciences cluster with far reaching social and economic benefits for the
province and Canada.
Genome BC's major investors are Genome Canada and the Province of British
Columbia. This funding is complemented by other private and public
investments.
Partnering meeting 희망여부
Company name: 56 Gail Rudakewich Biomedical Animation
Website: http://synapse-visuals.com/gail.htm
Contact Person: Gail Rudakewich, Tel: 416 453 3304. Email: [email protected]
Products and Services: Products and Services:
24
Gail Rudakewich is a biomedical animation and illustration company that offers
creative artistic skills to communicate complex medical and scientific ideas in a
dynamic visual form. Gail produces 3D animations and illustrations that
accurately convey a client’s vision. Gail’s clientele is varied and includes medical
science professionals from hospitals and academic institutions, and companies
in the biotechnology & pharmaceuticals industry.
Partnering meeting 희망여부
Company name: 57 Eurand International S.p.A.
Website: http://www.eurand.com/
Contact Person: Via Martin Luther King, 13 20060, Pessano con Bornago
Milan. Tel: +39-02-95428-1. Fax: +39-02-9574-5012.
Email: [email protected]
Products and Services: Products and Services: Via Martin Luther King has leveraged our proprietary
drug delivery technologies to develop a diverse product portfolio in a range of
therapeutic areas. Their current product portfolio includes their own proprietary
pharmaceutical products, co-development programs, and products that are
enhanced versions of existing drugs available for licensing.
Whether developed in-house or in conjunction with a valued client, their
pharmaceutical products are a testament to the innovation and broad application
of our technologies. Currently, more than 40 products using our technologies are
commercialized worldwide.
In 2005, they received approval in the United States for an ANDA version of a
marketed drug. In early 2007, they completed two phase III trials for a life-saving
product that is used in the treatment of Exocrine Pancreatic Insufficiency, a
disease often associated with cystic fibrosis and chronic pancreatitis, among
others.
Partnering meeting 희망여부
Company name: 58 Ergomed GmbH
Website: http://www.ergomed-cro.com/
Contact Person: Frankfurt Biotechnology Innovation Centre, Altenhöferallee 3 D-60438 Frankfurt
am Main. Tel: +49 (0) 69 / 95 11 74 – 0. Fax: +49 (0) 69 / 95 11 74 – 71. Email:
Products and Services: Products and Services: The ERGOMED Group is a pan-European Clinical
Development Company, providing full clinical trial-related services to developers
of medical drugs. ERGOMED can assist with strategic clinical development
planning, individual study design, project management and monitoring, study site
management, drug safety monitoring and pharmacovigilance, medical writing as
25
well as data management, biostatistics, regulatory assistance and other
services. In addition, ERGOMED has access to its own Phase 1 unit for healthy
volunteer studies as well as those in special populations and early phase
oncology studies.
With its headquarters in Frankfurt, Germany, and five operational centres in
London, Zagreb, Novi Sad, Krakow, and San Antonio ERGOMED currently
conducts operations in over 20 different European countries. ERGOMED
specializes in the fields of Oncology/Hematology and Neurology, with added
strengths in Endocrinology and Immunology. while retaining experience in many
other therapeutic areas and indications.
ERGOMED provides clinical development services to some of the world’s largest
pharmaceutical companies as well as to many small- and mid-sized drug
development companies and has been responsible for the pivotal studies of
several drugs including a number of oncologics which have gone on to receive
European regulatory approval. ERGOMED’s success is due largely to its
motivated, highly trained, experienced and dedicated workforce.
Partnering meeting 희망여부
Company name: 59 Karo Bio AB (Swedish company)
Website: http://www.karobio.com/en/
Contact Person: Carl-Magnus Andersson, VP, Discovery Research, Sweden,
Products and Services: Drug discovery and development company specializing in nuclear receptors for
the development of novel pharmaceuticals with focus on metabolic diseases.
Holding strong project portfolio with innovative molecules that primarily targets
diseases such as diabetes, atherosclerosis, dislipidemia. Undertaking two
clinical and four preclinical projects. Announced that an Estrogen receptor
compound discovered as part of its research collaboration with Merk & Co., Inc.
(Entered Phase I clinical development)
Target market : Holding innovative compounds for cardiovascular disease,
diabetes and depression areas. Karo Bo will seek a partner to bring eprotirome
through phase III clinical trials and to the market The aim is to initiate a
collaboration after completion of Phaswe IIb clinical trials.
Partnering meeting 희망여부
Company name: 60 Leukemia & Lymphoma Society
Website: http://www.leukemia-lymphoma.org/all_chap
Contact Person: THE WESTERN CANADA CHAPTER
26
310-1682 West 7th Avenue Vancouver, BC V6J 4S6
(604) 733-2873 (866) 547-5433 (Toll Free) (604) 733-2848 (Fax)
Products and Services: The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health
organization dedicated to funding blood cancer research, education and patient
services. The mission of LLS is to cure leukemia, lymphoma, Hodgkin's disease
and myeloma, and improve the quality of life of patients and their families. Since
its founding in 1949, LLS has invested more than $600 million for research
specifically targeting blood cancers.
The Leukemia & Lymphoma Society's Home Office is based in White Plains, NY.
Some Home Office staff are also based at regional offices in Alexandria and
Cincinnati.
Partnering meeting 희망여부
Company name: 61 Medical College of WI Research Foundation
Website: http://toolkit.wi.gov/education.htm
Contact Person: Dr. Joseph Hill Phone : 414-456-4381 [email protected].
The MCW Research Foundation links business with the research capabilities,
technology license opportunities, and clinical trial services of the Milwaukee-
based Medical College of Wisconsin, which has an annual R&D budget of $120
million. The research foundation is also launching a technology-transfer fund.
Partnering meeting 희망여부
Company name: 62 Meditrina Pharmaceuticals, Inc.
Website: http://www.meditrina.com/
Contact Person: 300N Fifth Avenue, Suite 150 Ann Arbor, MI USA 48104
(734) 926-0966
Products and Services: Meditrina Pharmaceuticals, Inc. identifies and repurposes already marketed
therapies and product candidates at advanced stages of development for new
indications focused on improving women’s health disorders with unmet medical
needs. The Company’s initial focus includes gynecologic and aromatase-
meditated conditions such as endometrial thinning prior to hysteroscopic
procedures including endometrial ablations, ectopic pregnancies, endometriosis
and uterine fibroids.
Meditrina is currently conducting phase II clinical trials with
Femathina™ (MPI-674) towards improving outcomes for women who
undergo endometrial ablations to treat abnormal uterine bleeding
(AUB). MPI-674 is an aromatase inhibitor (AI) with a well-established,
multi-year chronic safety and tolerability profile that Meditrina is
27
repurposing to improve patient outcomes for this indication. Currently
used for the chronic treatment of estrogen-dependent breast cancer in
postmenopausal women, AIs are being investigated in a variety of
women’s health conditions. Meditrina holds the exclusive worldwide
rights to patent applications covering several uses of AIs in
gynecologic indications.
Partnering meeting 희망여부
Company name: 63 MedPharm Ltd
Website: http://www.medpharm.co.uk/
Contact Person: Mr. Paul Barrett
Head of Business Development
Surrey Research Park United Kingdom 44 (0)1483 457580
Products and Services:MedPharm is a private drug delivery and contract service company committed to
the creation and development of novel systems, particularly for topical drug
formulations for delivery to the skin, nail, mucous membranes, eye, nose and
lung. Success reputation with formulating difficult compounds especially in the
area of topical drug delivery.
With over 100 customers worldwide, MedPharm offers a unique and highly
specialized service in pharmaceutical contract research and development, and
expert project management from feasibility tests, dosage design and
optimization, to preparation of GMP clinical supplies trials and preclinical (GLP
and non-GLP) and clinical evaluation. MedPharm has a substantial patent
portfolio of novel drug delivery systems. These technologies are available as part
of service offering or as stand-alone licen s es to third parties .
Partnering meeting 희망여부
Company name: 64 Merck & Co., Inc.
Website: http://www.merck.com/pubs/
Contact Person: New Jersey, USA Phone: 908-423-1000
Products and Services: Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated
to putting patients first. Established in 1891, Merck discovers, develops,
manufactures and markets vaccines and medicines to address unmet medical
needs. The Company devotes extensive efforts to increase access to medicines
through far-reaching programs that not only donate Merck medicines but help
28
deliver them to the people who need them. Merck also publishes unbiased
health information as a not-for-profit service.
Partnering meeting 희망여부
Company name: 65 metanomics GmbH
Website: http://www.metanomics.de/aboutus.html
Contact Person: Berlin Germany, Phone: +49 30 348 07 - 0
Products and Services: Founded in July 1998 as a joint venture between the BASF AG and a group of
scientific staff at the Max-Planck-Institute of Molecular Plant Physiology.
is currently tailoring some 2500qm of lab and office space for
company specific requirements.
is organized into four technical centres; genomics, plant
production, bio-analytics and bio-informatics. In addition to the company internal
agenda in the area of functional genomics metanomics is keen to engage in
further partnerships in all four of technical centers.
Partnering meeting 희망여부
Company name: 66 MiCardia Corporation
Website: http://www.micardia.com/
Contact Person: Irvine California USA [email protected]
Tel: +1.949.951.4888 Fax: +1.949.951.4812
Products and Services: MiCardia Corporation is an early stage venture dedicated to designing,
developing and commercializing minimally invasive methods to treat heart valve
disease – Mitral Valve Regurgitation (MR), Tricuspid Valve Regurgitation and
Congestive Heart Failure (CHF).
the company has built an experienced technical and clinical team, while creating
a comprehensive intellectual property portfolio. Proof of concept has been
completed for a Dynamically Activated Annuloplasty Ring with novel methods for
off-pump intra-operative and chronic percutaneous activation methods.
MiCardia has developed an array of advanced annuloplasty rings which may be
adjusted dynamically after they are surgically placed in either the mitral valve
annulus and/or tricuspid valve annulus position(s).
The technology allows changes to the shape and the size of the annuloplasty
ring while viewing the modifications in real time via echo (ultrasound), without
requiring additional invasive surgery.
29
Partnering meeting 희망여부
Company name: 67 Micromet GmbH
Website: http://www.micromet.de
Contact Person: HQ: Bethesda MD USA Munich Germany
Phone: +49 (0) 89 895277-0
Products and Services: Listed on NASDAQ
Market : Cancer, inflammation, autoimmune diseases
Current partner: MedImmune, Merck Serono, Morphotek, Nycomed, Tracon
Pharmaceuticals
Micromet's goal : To build a well-staged pipeline of highly differentiated products
for the treatment of cancer, inflammation and autoimmune disease. All drug
candidates are derived from antibodies.
Technology : BiTE Antibody Platform
http://www.micromet.de/index.php?id=124 – Clinical and Preclinical Pipeline
overview
Partnering meeting 희망여부
Company name: 68 Modigene Inc.
Website: http://www.modigeneinc.com/
Contact Person: Israel Phone: 866-644-7811 Fax: +(972)-8-9300091
Products and Services: Modigene is a biopharmaceutical company utilizing patented technology to
develop longer-lasting, proprietary versions of already approved therapeutic
proteins that currently generate billions in annual global sales.
Technology : Modigene`s core technology is the use of a short, naturally
occurring amino acid sequence (ctp) to slow the removal of therapeutic
proteins from the body without increasing toxicity or altering the oberall
biological activity.
Product : Human Growth Hormone, Erythropoietin, Interferon B
Future Products :
Dramatically reduce the number of interventions required to achieve the
same therapeutic effect from the same dosage; e.g. reduce the number of
injections needed from a daily schedule to weekly.
30
Gain extended patent protection as proprietary new formulations of existing
therapies;
Achieve faster commercialization with lower risks and costs than those
typically associated with a new therapeutic protein; and
Be manufactured using industry standard biotechnology based protein
production processes.
Interested in licensing out : Modigene is pursuing licensing deals with
biotechnology companies that have a strategic interest in using our solution
to develop longer-lasting versions of their existing therapeutic proteins or
peptides.
Partnering meeting 희망여부
Company name: 69 Nektar Therapeutics
Website: http://www.nektar.com/wt/home/index
Contact Person: HQ in San Diego CA, USA, Alabama, India [email protected]
Products and Services: Nektar developing our own high-value, proprietary products as well as highly
differentiated products in partnership with leading pharmaceutical and
biotechnology companies. Nektar development programs focus on products
that fill unmet needs in diabetes, infectious disease, oncology, and eventually
other areas, where they can have significant impact
As the product portfolio and pipeline continue to grow, so does the company
capacity for innovation. Nektar continues to expand worldwide capabilities,
explore new opportunities, and bring fresh perspectives to medicine.
Pipeline overview : http://www.nektar.com/wt/page/detailed_pipeline
Drug Development Platform (Interested in licensing out) : Nektar’s proprietary
technologies have the potential to increase significantly the therapeutic value
of medicines by enhancing drug performance, increasing patient acceptance,
improving patient outcomes, and redefining disease management. These
technologies are the foundation of our proprietary products and are made
available to our pharmaceutical and biotechnology partners.
Partnering meeting 희망여부
Company name: 70 Nerites Corporation
Website: http://www.nerites.com/
31
Contact Person:HQ: Madison, WI USA Phone: 608-443-2440
Email: [email protected]
Products and Services: Product : Medical devices to aid tissue repair speed surgical times, and
reduce postoperative complications. Nerites portfolio of surgical adhesive
and coating products can be used to : Close internal tears and volds, Affix
synthetic and biologic devices, prevent bacterial biofilm formation and
postsurgical adhesions, immobilize local therapeutics.
Technology : Nerites™ was inspired by marine mussels and the remarkable
substance they secrete to bond to underwater surfaces. Nerites scientists
create synthetic mimetics of these proteins and use them to build adhesive
polymers that can be tailored to fit a broad variety of indications. Products are
typically delivered in situ as a hydrogel, liquid, or spray, or they can be pre-
coated onto an adjunctive medical device. The innovation and subsequent
applications are thoroughly patent-protected.
Interests : To seeks corporate partners for specific medical indications.
Partnering meeting 희망여부
Company name: 71 Neurobiological Technologies Inc.
Website: http://www.ntii.com/
Contact Person: Emeryvill, CA Telephone: (510) 595-6000
Products and Services: A biotechnology company engaged in the business of acquiring and developing
central nervous system (CNS) related drug candidates. The company is focused
on therapies for neurological conditions that occur in connection with dementia,
Alzheimer's disease, ischemic stroke, neuropathic pain, and brain cancer.
Interests : Licensing In - The company employs a strategy of in-licensing late-
stage CNS agents and pursues regulatory approval and commercialization either
independently or with a strategic partner.
Product : NAMENDA® (memantine hydrochloride) received approval for the
treatment of Alzheimer's disease in Europe in 2002 and in the U.S. in 2003. In
the U.S., NAMENDA is currently being sold by Forest Laboratories for moderate-
to-severe Alzheimer's disease. In Europe, memantine has been marketed by
Merz & Co. for a number of indications for several years. For Alzheimer's
disease, memantine is now being sold by Merz's European marketing partner H.
Lundbeck. Under an exclusive marketing agreement, the company will receive
royalty payments by Merz and its marketing partners from sales of memantine
32
for Alzheimer's disease.
Marketed : Memantine (Moderate-to-Severe Dementia and Alzheimer ’ s Disease
Phase III : VIPRINEX (Acute Ischemic Stroke) XERECEPT ( bAgent being
investigated for the treatment of brain swelling associated with brain tumors)
Partnering meeting 희망여부
Company name: 72 Neuroimage Inc
Website: http://neuroimageinc.com/
Contact Person: Ontario, Canada. Dr. Adolfo Cotter, President / Senior consultant
T) 416-457-5699
Products and Services: Components : 1) An ongoing consulting business focused on brain imaging and
other areas of neuroscience, 2) Self-directed research and development into the
brain-mind interface
Service : Image Acquisition (in collaboration with Douglas Hospital affiliated with
McGill University
Brain imaging processing and analysis (statistical data), Biostatistics, preclinical
pathology studies
R&D : Research to discover more about the biological basis of cognition.
Interests : To explore the market opportunities on the followings;
1) Creative machines (Machine to produce ideas that will complement and
enhance the brain’s ability to be creative.
2) Neuroinformatics (combination of information technology and brain
discovery indifferent domains (data mining, thought and mood
processes)
Partnering meeting 희망여부
Company name: 73 NextGen Sciences
Website: http://www.nextgensciences.com/
Contact Person: Ann Arbor Michigan 48108
t: +1-866-973-7914 (toll free) [email protected]
Products and Services: Service : NextGen Sciences, located in Ann Arbor, MI, offers a suite of
biomarker services for research and development called biomarker express™.
The development of protein biomarker assays has been a bottleneck in the drug
development pipeline for years. biomarker express™ services utilize proprietary
methods to significantly decrease timelines and increase the traditionally low
success rates associated with the various stages of biomarker development.
33
These services include:
1. discoveryexpress™ - the discovery of new biomarkers from biological
samples (differentially expressed proteins)
2. assayexpress™ - the development of peptide MRM (pMRM) assay to
quantitate proteins in biological samples
3. testingexpress™ - the testing of biological or clinical samples to quantify
the proteins in the pMRM assays developed in assayexpress™
4. biomarkerlibrary™ - a biomarker knowledgebase to aid researchers and
clinicians in selecting the best biomarkers for each R&D program.
Partnering meeting 희망여부
Company name: 74 NextPharma Technologies
Website: http://www.nextpharma.com/
Contact Person: North America Mr. Rich Koch
T) +1-847-382 5803 Email: rich.koch(at)nextpharma-us.com
Products and Services: NextPharma is one of the leading contract manufacturers in Europe for the
pharmaceutical, biotechnology and health care industries.
Service : Technology service on Product development, manufacturing and
packaging, cold chain & logistics. (Analytics, Microbiological testing, clinical trials
services)
Having s eparate production units for cephalosporins, penicillins and cytostatics .
Solutions such as sustained release and time release formulations/pellets as
well as ampoules and effervescent tablets, conventional dosage forms such as
tablets, capsules, sugar coated tablets, dry syrups, sachets, ointments and
liquids.
Partnering meeting 희망여부
Company name: 75 Novacta Biosystems Limited
Website: http://www.novactabio.com/
Contact Person: BioPark Hertfordshir, UK Dr. Georg Buchner MBA - VP of Corporate and
Business Development Tel:+44 (0)1707 356130 +44 Fax:(0)1707 356131
Products and Services: Novacta Biosystems is now focussed solely on offering ‘fee for service' activities
to blue chip drug development and biofuel companies . Novacta is providing
solutions for chemical challenges using Metabolite Factory Technology,
biocatalysis capabilities and pathway engineering in bacteria, algae and yeast.
34
Service : Spun out from GloxoSmithKline’s Biotransformation and Natural
product chemistry center in 2003.
Technology : Biocatalysis use the selective catalytic power of our proprietary
collection of enzymes and micro-organisms under mild conditions. It can improve
the economic and environmental impact of chemical syntheses and processes.
Partnering meeting 희망여부
Company name: 76 Numerate, Inc.
Website: http://www.numerate.com/
Contact Person: San Bruno CA USA T) +1 (650) 472 0632
[email protected] Mr. Kevin Kaster Business Development
Products and Services: Service : Drug Engineering Process (two key breakthroughs) :
Accurately predicting the activity, ADME and toxicity of small molecule drugs.
Numerate has invented machine learning algorithms to deal with the noise and
biased nature of biological data to build models that are as accurate as
laboratory assays.
Numerate models are ligand-based and therefore do not require the crystal
structure of the target protein. Numerate models are also applicable to
metabolism, PK, and certain safety-related issues. (Generating and searching)
(Validation : successfully applied to several therapeutic programs)
Partnering meeting 희망여부
Company name: 77 OncoGeneX Technologies Inc.
Website: http://www.oncogenex.ca/
Contact Person: Canadian Headquarters : Vancouver, British Columbia Canada
Telephone: (604) 736-3678 Fax: (604) 736-3687
Dr. Martin Gleave MD, Chief Scientific Officer
Products and Services: A biopharmaceutical company committed to the development and
commercialization of new cancer therapies that address unmet needs in
the treatment of cancer. OncoGenex has a deep oncology pipeline, with
each product candidate having a distinct mechanism of action and
representing a unique opportunity for cancer drug development.
Product Pipeline : OncoGenex currently ha s five product candidates in
development: OGX-011 (five Phase 2 clinical trials, completed patient
35
enrollment) In July 2008, reached an agreement with US FDA on the
design of a Phase 3 registration trial via SPA process , OGX-427, SN2310,
CSP-9222 and OGX-225. Three of the products are in clinical
development.
http://www.oncogenex.com/products/index.html
Partnering meeting 희망여부
Company name: 78 Oncolytics Biotech Inc.
Website: http://www.oncolyticsbiotech.com/
Contact Person: Mr. Nick Hurst The Equicom Group
Calgary, Alberta Tel:403.538.4845 [email protected]
Products and Services: Oncolytics Biotech Inc. focuses on the discovery and development of
pharmaceutical products for the treatment of a wide variety of human cancers.
Headquartered in Calgary, Alberta, Canada, the Company was formed in 1998 to
explore the oncolytic capability of the reovirus, a virus that preferentially
replicates in cells with an activated Ras pathway, one of the most common family
of genetic defects leading to cancer.
Product: The Company’s technologies are based on discoveries made in the
1990s in the Department of Microbiology and Infectious Diseases at the
University of Calgary. The potential products are being developed using the
naturally occurring reovirus for treatment of cancers in humans. Since PKR is
responsible for preventing reovirus replication, tumour cells lacking the activity of
PKR are susceptible to reovirus infection and eventual cell death. Progeny virus
particles are then able to infect and kill surrounding cancer cells. This cycle of
infection, replication and cell death is believed to be repeated until there are no
longer any tumour cells carrying an activated Ras pathway available.
Oncolytics has discovered that tumour antigens generated by this viral oncolysis
may educate the immune system to recognize and kill tumour cells. Oncolytics'
clinical program includes human trials using REOLYSIN® alone and in
combination with radiation and chemotherapy.
Partnering meeting 희망여부
Company name: 79 Orcrist Bio Inc.
Website: http://www.orcristbio.com/
Contact Person: Calgary, AB CANADA Tel: (403) 984-3882
Email: [email protected]
Products and Services: Orcrist Bio Inc. is a biotechnology company dedicated to developing and
36
commercializing promising therapeutics. Located in Calgary, Alberta.
Product : Orcrist Bio Inc’s lead program Orcrist’s lead program centers on
HYC750, an exciting candidate drug for treating a serious and common side-
effect of chemotherapy treatment for cancer - suppression of the patients' white
blood cell production.
Interests : The company is actively looking to add to its pipeline through in-
licensing opportunities.
White blood cell depletion is a multi-billion dollar market, and initial research has
shown that HYC750 has the potential to be a more effective, safe and affordable
alternative to current commercially available mobilizers. T he company is
currently pursuing a co-development agreement with a US-based stem cell
company actively working with complimentary technology to evaluate HYC750’s
efficacy in this indication.
Partnering meeting 희망여부
Company name: 80 Outsourcing Clinical Trials
Website: http://www.out-clinicaltrials.com/
Contact Person: 8/2 Bolshaya Moskovskaya Str., Suite 4-1, St.Petersburg, 191002, Russia
Business Development Manager: Ms. Alexandra Zaichenko Phone: +7 812
449 86 34 Email: [email protected]
Products and Services: OUTSOURCING CLINICAL TRIALS (OCT) is a contract research organization
(CRO) with head office in St. Petersburg, Russia. The company provides
services to Pharmaceutical, Biotech, and Nutraceutical companies interested in
conducting clinical trials in Eastern and Central Europe with 7 offices in Russia,
Ukraine, Baltic States, Bulgaria, Belarus, US and free-lance presence in Austria,
Czech, Costa Rica, Germany, Greece, Hungary, Israel, Italy, Mexico, Poland,
Slovakia, others.
Service : High quality data/services Clinical trial services
Partnering meeting 희망여부
Company name: 81 Penn Pharmaceuticals
Website: http://www.pennpharm.co.uk/
37
Contact Person:Corporate Headquarters : Gwent, South Wales, UK
Telephone: +44 (0) 1495 711222
Email: [email protected]
Products and Services: Service : A suite of drug development, clinical trial supply and consultancy
services enables us to offer a fully integrated and personal service to our clients.
- Formulation development, Analytical development, clinical trial packing and
labeling, storage & distribution, CMC Consultancy services, Qualified Person
Release services
Technologies & Capabilities : Facilities & Equipment, High Containment
processing, Paediatric formulation & manufacture, Semi-solids form expertise
Partnering meeting 희망여부
Company name: 82 Pfizer Inc
Website: http://www.pfizer.com/home/
Contact Person: New York, NY 10017 USA
Phone: 1-212-733-2323
Products and Services: Pfizer is the world's largest research-based biomedical and pharmaceutical
company. Major research and development locations in the United States
and England. Recent innovations include Sutent®—a novel cancer medicine
that both cuts off the blood supply that feeds tumors and destroys cellular
reproduction, and Chantix™—a new prescription medicine and
accompanying support plan designed specifically to help smokers quit. In
2007, Pfizer earned $48.4 billion in revenues and invested $8.1 billion in
research and development.
Partnering meeting 희망여부
Company name: 83 Pharmatek Laboratories, Inc.
Website: http://www.pharmatek.com/
Contact Person:San Diego, California 92121 T) 1-858-805-6383
Products and Services: A pharmaceutical chemistry development organization supporting the
pharmaceutical and biotechnology industries. Pharmatek focuses on bringing
client compounds from discovery to the clinic with services that include
compound selection , analytical development , preformulation testing , formulation
development , GMP manufacturing , ICH stability storage and testing , and high-
potent & cytotoxic development and manufacturing .
38
Product : Pharmatek Laboratories' Hot Rod Chemistry® (HRC) is a formulation
screening kit designed to solubilize drug candidate compounds and prepare
them for testing in animal models.
Each HRC® kit contains eight non-toxic, orally available formulations that
increase the solubility, bioavailability and stability of drug candidates. Each
formulation has been created using functional excipients that are GRAS and can
be found in FDA approved therapeutics.
Partnering meeting 희망여부
Company name: 84 Piramal Healthcare
Website: http://www.npilpharma.com/
Contact Person: Head office : Mumbai, India Tel: +91-022-3046 6660
US office : Edison New Jersey Tel : +1( 732) 549 9451
Products and Services: Pharma Solutions is one of the very few Contract Manufacturing Organizations
(CMOs) that can provide end-to-end support for bringing a drug to market or
managing the life cycle of a launched drug.
Service : Clinical Phase API synthesis and Formulations Development services
and scale up to Commercial API and Finished Dosage form supply.
Process Development, synthesis and scale-up of API for Clinical phase studies
Commercial manufacturing of APIs at global network of facilities spread across
India, UK and North America
Drug development services including preformulations studies, formulations
development, CTM supply, clinical packaging & distribution and clinical trials at
in-house CROs
Commercial manufacturing of finished dosage forms (including hormonal
products) across global network of sites
Partnering meeting 희망여부
Company name: 85 Priaxon
Website: http://www.priaxon.com/content/home/index.php
Contact Person: Munich Germany
Tel.: +49 (0) 89 / 4521308-0 [email protected]
Products and Services: Priaxon opens up a new dimension in drug discovery by a unique combination of
proprietary chemoinformatic tools with innovative synthetic chemistries.
39
Technology : design and prediction tools: Proprietary algorithms superior in
speed and accuracy for design, similarity and property prediction within very
large chemical space. Priaxon uses this integrated technology as a service
provider in collaborations with customers reaching from regional biotech
companies up to big pharma.
Service : Integrated approach, MCR, Chemoinformatics, Drug discovery, D
Therapeutic programs, Chemistry services
Partnering meeting 희망여부
Company name: 86 Prince Edward Island Business Development
Website: http://www.peibusinessdevelopment.com/
Contact Person: N/A
Products and Services: The Government of Prince Edward Island for the economic development
Partnering meeting 희망여부
Company name: 87 Procter & Gamble
Website: http://www.pg.com/en_US/index.shtml https://secure3.verticali.net/pg-
connection-portal/ctx/noauth/0_0_1_4_83_4_13.do
Contact Person: N/A
Products and Services: P&G Needs posted on the web site
Partnering meeting 희망여부
Company name: 88 ProPharma Partners International Inc.
Website: http://www.propharmaipartners.com/
Contact Person: N/A
Products and Services: N/A
Partnering meeting 희망여부
Company name: 89 Protalix Biotherapeutics Ltd
Website: http://www.protalix.com/
Contact Person: Mr. Yossi Maimon, CFO, Israel.
T: +972-4-902-8100, Extension 143 E: [email protected]
Products and Services: A biopharmaceutical company focused on the development and
commercialization of recombinant therapeutic proteins based on Protalix
proprietary ProCellEx™ protein expression system. Using our ProCellEx™
system Protalix is developing a pipeline of proprietary recombinant therapeutic
proteins based on our plant cell-based expression technology that target large,
40
established pharmaceutical markets and that rely upon known biological
mechanisms of action.
Technology : Procellex Platform technology, Protein production Protalix's novel
bioreactor plant cell system, based on disposable plastic vials
Product : Glucocerebrosidase
Pipeline Product : ProCellEx™ protein expression system, with an emphasis on
treatments. The company identified several product candidates oriented towards
specialty disease and therapeutic market segments, including treatments for
Fabry disease and female infertility. The company plans to file an
investigational new drug application (IND) with the FDA with respect to at least
one additional product during 2008. In addition, we are developing a new method
for delivering active recombinant proteins systemically through oral
administration of transgenic plant cells expressing such biotherapeutic proteins.
PRX-102, PRX-111, Acetylcholinesterase
Partnership and licensing In addition to our main line of therapeutic products,
we also rely on partnership opportunities and licensing agreements to develop
and maintain our competitive position. We are currently partnered with several
world-renowned pharmaceutical companies and leading scientific institutions.
Research undertaken to evaluate the potential for the developed
acetylcholinesterase and its variants, for various therapeutic fields. To date, our
in vitro experiments have shown that the acetylcholinesterase expressed in our
ProCellEx™ expression system demonstrates promising biological activity on
biochemical and cellular levels.
Partnering meeting 희망여부
Company name: 90 Protein Forest, Inc.
Website: http://www.proteinforest.com/
Contact Person: Lexington MA USA Phone: 617-926-4778
Email: [email protected]
Products and Services: Protein Forest, Inc. (founded in 2002) is a proteomics tools company. The
company develops, manufactures and markets instruments, consumables and
software products to scientists around the world.
Product : The initial product lines utilize a new technology called parallel
isoelectric focusing which is incorporated into the digital ProteomeChip™
(dPC™). The first applications addressed are Mass Spectroscopy (MS) sample
41
prep and Western Blotting. The digital ProteomeChip™ product line brings
unmatched speed, reproducibility and high resolution in an easy to use format.
The company also develops and markets data analysis software called Mass
Spec Results Analysis Tools (MSRAT™) that allows scientists of any discipline
to discover the richness of their dPC™ results within minutes.
Future applications of the technology include isoelectric protein purification,
automated systems and 2D dPC™ formats. U.S Patent 7,166,202 is issued for
the dPC™ platform.
Protein Forest® is dedicated to the development, manufacture and marketing of
leading-edge products to boost the researcher's ability to correlate protein
expression, post-translational modifications
Technology : The dPC™ Fractionation Technology
The dPC™ separates complex biological samples into fractions suitable for
mass spectroscopy, chromatography and blotting using the principle of parallel
isoelectric focusing.
Partnering meeting 희망여부
Company name: 91 Proteos, Inc.
Website: http://www.proteos.net/
Contact Person: Kalamazoo, MI 49008 T) 269.372.3423 [email protected]
Products and Services: Specialized in protein production, expression and purification
Service : Protein expression, Protein purification, Peptide Service
Product : Proteos now provides crystallographic grade recombinant human
renin. As a major supplier of recombinant human renin, Proteos is providing
highly purified and characterized enzyme to customers all over the world.
(Recombinant Human Renin, Recombinant Human Prorenin, Recombinant
Human Renin C-terminal hexa-His tag, Recombinant Human Prorenin C-terminal
hexa-His tag, recombinant Human BACE
Expertised in the production of highly pure BACE (beta-site APP cleaving
enzyme) from E. coli for crystallography.
Partnering meeting 희망여부
Company name: 92 PRUDENTAS LLC
Website: http://www.prudentas.com/
Contact Person: Moscow, Russia Tel. +7 495 628 3802 [email protected]
42
Products and Services: PRUDENTAS is a Contract Research Organization (Limited Liability Company)
registered in March 2007.
Expertise : Pharmaceutical companies and CROs covers the successful
conduct of large-scale studies in multiple centers in Russia, Ukraine and Baltic
States. Extensive experience in conducting Phases Ib-IV clinical trials for
different groups of patients (adults, children) in various therapeutic areas:
Current clinical trials in patients with:
Severe COPD (Phase II); Renal Cell Carcinoma (Phase IIIb); HIV (Phase II);
Crohn Disease (Phase II) ; Hemophilia (Phase Ib) ; Multiple Sclerosis (Phase IV)
Cardiovascular (Phase IV)
Service : Phase I – IV trials in Russia and Ukraine: Regulatory support of the
study, clinical trial monitoring, GCP Auditing, GVCP training for investigators,
Medical monitoring, site management,
Partnering meeting 희망여부
Company name: 93 QSV Biologics Ltd.
Website: http://www.qsvbiologics.com/
Contact Person: Edmonton, Alberta, Canada
Phone: (780) 438-5722 [email protected]
Products and Services: QSV Biologics provides dedicated biopharmaceutical contract manufacturing
services for process development & scale-up, pre-clinical research, Phase I, II
and III clinical trial and commercial materials to biopharmaceutical firms
developing protein therapeutic products.
QSV was issued a Health Canada Commercial Establishment License in 2006.
Service : Process Development, Pre-clinical manufacturing, GMP
Manufacturing, Quality Assurance, Quality Control
Partnering meeting 희망여부
Company name: 94 Rules-Based Medicine, Inc.
Website: http://www.rulesbasedmedicine.com/
Contact Person: Austin, TX USA [email protected]
Phone 512-835-8026
Products and Services: Biomarker testing laboratory delivering reproducible, quantitative, multiplexed
immunoassay data. The company provides comprehensive protein biomarker
products and services based on its Multi-Analyte Profiling (MAP) technology platform.
Product & Service : The company use s Multi-Analyte Profiles (MAPs) to measure from
several to hundreds of proteins in a small sample. Simply send us acceptable samples
43
(see under "How to Order and Ship") for either HumanMAP or RodentMAP analysis and
the company will send you the data in about two weeks. For either MAP, we measure all
of the analytes found in the quantitative antigen panel. MAP analysis, data mining
Partnering meeting 희망여부
Company name: 95 Sandoz International GmbH
Website: http://www.sandoz.com/site/en/index.shtml
Contact Person:
Products and Services: Sandoz makes over 5,000 different doses of generic pharmaceuticals and
biotechnological drugs. As the generics arm of Swiss drug firm Novartis AG,
Sandoz develops products including antibiotics and hormone therapies, as well
as treatments for cardiovascular, central nervous system, and gastrointestinal
disorders. Sandoz produces finished dosage forms of such off-patent drugs as
Duragesic (Fentanyl) and GERD drug Prilosec. It also develops active
pharmaceutical ingredients used by other companies to form finished products.
Beyond the more common tablet form generics, Sandoz manufactures more
complex generics in different delivery systems including patches and inhalers.
Partnering meeting 희망여부
Company name: 96 Selvita sp. z o.o.
Website: http://www.selvita.com/
Contact Person: Poland Phone: +48 12 410 73 80 [email protected]
Products and Services: Selvita is a product and solution provider for the pharmaceutical and
biotechnology industry. We deliver comprehensive solutions to the customers
from pharma & biotech industry targeted at lowering the cost of introducing
innovative therapeutical compounds to the market...
Service : Drug discovery ( custom in silico library construction) , Drug targeting &
reposition, Chemical synthesis (contract synthesis and syntheses paths
optimization) , IT for research Protein modeling platform, research project up to
the pre-clinical stage. (oncology, central nervous system, infections and
diagnostics)
Compound : SEL73 program, SEL92 program
Needs : compound with hypotensive activity available for partnering
Partnering meeting 희망여부
Company name: 97 SemBioSys Genetics Inc.
Website: http://www.sembiosys.ca/
44
Contact Person: Calgary AB, Canada. Partnership Inquiries: Mr. Phillip Stephan
Phone: 403.250.5424 Email: [email protected]
Products and Services: SemBioSys Genetics Inc. is a plant biotechnology company with a powerful
technology that enables production of high-value pharmaceutical and non-
pharmaceutical products in an affordable and sustainable manner. (production
solution for drugs needed in large quantities)
Product and Service : P lant technology can be applied to a wide variety of
product opportunities - including pharmaceutical (insulin for diabetes, Apo AI and
Apo AI Milano cardiovascular disease.) and non-pharmaceutical ( personal care
producers, nutritional oils (omega fatty acids) for use in a variety of consumer
goods, and applications for agricultural biotechnology .)
Goal : As SemBioSys pharmaceutical products become partnered, the company
will work towards identifying new products for our pipeline.
Partnering meeting 희망여부
Company name: 98 Signum Biosciences Inc.
Website: http://www.signumbiosciences.com/
Contact Person:NJ USA Phone) 732.329.6344 Email: [email protected]
Products and Services: Signum Biosciences is a private biotechnology company dedicated to developing
small-molecule therapeutics derived from its Signal Transduction Modulation
(STM) platform to modulate signal transduction imbalances. Through research
on protein networks that control biological systems, Signum is developing
therapeutic candidates for Alzheimer's, Parkinson's, diabetes, asthma and
certain skin conditions.
Signum is focused on therapeutics that are well protected by intellectual property
and are developing them for indications that can be commercialized in the near
term.
Interests : E xpect to out-license Signum products to both skin care and pharmaceutical
companies. Platform : G-protein-mediated signaling, protein phosphorvlation .
Pipeline : Focuses on the regulation of cellular signaling networks to develop
proprietary molecules to compensate for signaling imbalances that diminish
health and cause disease. Signum is commercializing high value cosmetic
ingredients and nutritional supplements as well as pharma candidates for major
diseases.
45
http://www.signumbiosciences.com/pipeline.html
Partnering meeting 희망여부
Company name: 99 Silence Therapeutics AG
Website: http://www.silence-therapeutics.com/
Contact Person: Berlin Germany, Chief Scientific Officer Klaus Giese +49 30 9489 2800
Products and Services: RNAi therapeutics in Europe. The company has proprietary short interfering
RNA (“siRNA”) molecules. Proprietary systemic delivery system, AtuPLEX. This
enables the delivery of siRNA molecules to targeted diseasede tissues and cells
in the body, whilst increasing their bioavilability and circulation times. R&D
collaboration with Astra Zneca to develop AtuRNAi against five specific targets
including those in respiratory indications.
Technology : considered one of the most exciting and significant medical
breakthroughs of recent years. RNAi offers the potential for the development of
novel therapeutics that silence specific genes involved in the initiation or
progression of any disease or disease process
Generated revenues of more than Euro 20M in collaboration with the major
customers.
Partnering meeting 희망여부
Company name: 100 Stem Cell Therapeutics Corp.
Website: http://www.stemcellthera.com/
Contact Person: Calgary, AB 403-245-5495
Products and Services: Canadian public biotechnology company focused on the development and
commercialization of drug-based therapies to treat central nervous system
diseases.
Product portfolio : NTx™-265, to treat acute stroke and secondary programs,
NTx™ 428 for traumatic brain injusry and NTx ™ 488 for multiple sclerosis.
Therapeutic approach is to enhandce the body’s inherent self-repair ability.
Partnering meeting 희망여부
Company name: 101 Stromedix, Inc.
MA U.S.A
Website: http://www.stromedix.com/
Contact Person: Cambridge MA 02141
tel 617.674.8400 [email protected]
Products and Services: Stromedix will focus initially on chronic indications but plans to leverage its
46
expertise and expand its therapeutic pipeline into related settings such as acute
organ failure and cancer.
STX-100 is Stromedix’ first clinical candidate and is being developed for the
treatment of chronic allograft dysfunction in kidney transplant recipients. STX-
100antifibre activity in pre-clinical models of lung, kidney, liver disease
Partnering meeting 희망여부
Company name: 102 Summit plc U.K.
Website: http://www.summitplc.com/
Contact Person: Oxfordshire
OX UK Tel: +44 (0) 1235 44 39 39 [email protected]
Products and Services: Summit plc is a leading UK biotechnology company that is focused on
discovering and developing proprietary new drugs to treat serious diseases
where there is currently a high and unmet medical need Pharmaceutical &
Biotechnology .
Technology : Carbohydrate chemistry -Naturally occurring source of new drugs.
An emerging technology. Zebrafish biology - Accelerates the drug discovery
process, Reduces the attrition rate, Reduces the development costs
Partnering meeting 희망여부
Company name: 103 SuperGen Inc.
Website: http://www.supergen.com/
Contact Person: Timothy L. Enns Sr. Vice President, Dublin Bld. Dublin CA
Ph)925-560-0100 [email protected]
Products and Services SuperGen boasts a development pipeline of several promising compound
classes at various stages of development with good drug like properties,
ensuring a steady flow of novel therapeutics into the clinic.
http://www.supergen.com/subpages/prod-dev.asp
Product : Abstract 532 EORTC-NCI-AACR 2006 c-MET Inhibition
Radiosensitizes Melanoma by Inhibiting Double Strand DNA Repair .
Abstract 1540 AACR 2007 Annual Meeting MP470.HCL, a Potent
Suppressor of Rad51, I mproves Bioavailability and Tolerability Abstract
4028 MP470 a potent suppressor of Rad51, improves response to
platinum-based anticancer agents. Abstract 5421, Abstract 1026,
Abstract 671, Abstract 4083,
Partnering meeting 희망여부
47
Company name: 104 SuppreMol GmbH
Website: http://www.suppremol.com/
Contact Person: Martinsried/Munchen Germany
Tel: +49 (0)89 30 90 50 680 Email: [email protected]
Products and Services:Company is focused on the development of soluble Fcγ-Receptors (sFcRs)
which are recombinant autologous therapeutic proteins endowed with a proven
strong immunosuppressive potential
http://www.suppremol.com/technology.php
SuppreMol is developing soluble Fcγ-receptors (sFcRs) for the treatment of
autoimmune diseases such as Idiopathic Thrombocytopenic Purpura (ITP),
Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). The most
advanced program is an sFcR for ITP. SuppreMol will also develop this sFcR for
SLE and RA.
In addition the Company promotes an Anti-FcγRIIb monoclonal antibody to target
FcRs for therapeutic interventions in autoimmune diseases.
Partnering meeting 희망여부
Company name: 105 Synapse Visuals
Website: http://www.synapse-visuals.com/
Contact Person: M.Gail Rudalkewich [email protected]
Products and Services: Synapse Visuals have the knowledge and the insight to develop creative and
effective solutions for slide show or power point presentation, web site or
interactive CD-ROM program, academic publication, brochure or poster.
Partnering meeting 희망여부
Company name: 106 Technology Vision Group LLC
Website: http://www.techvision.com
48
Contact Person:CA USA Phone: +1.831.464.4230
Products and Services Technology Vision Group LLC (TVG) is a leading life science business
development company. Since 1992, TVG has been developing innovative
methods to help life science companies attract partners and investors, acquire
new products and technologies, and achieve a variety of strategic business
development goals.
Partnering meeting 희망여부
Company name: 107 TGen Drug Development Services
Website: http://www.td2.org
Contact Person: Tara Monteleone (Arizona USA)
Manager, Business Development
Phone (602) 358-8322 [email protected]
Products and Services TGen Drug Development Services (TD2) offers cost-reduction programs
through advanced technology and economies-of-scale, along with
comprehensive billing to accommodate your budget parameters.
Partnering meeting 희망여부
Company name: 108 Transcept Pharmaceuticals
Website: http://www.transcept.com
Contact Person: Richmond, CA 94804 Phone: 510.215.3500
Products and ServicesA specialty pharmaceutical company focused on the development and
commercialization of proprietary products that address important therapeutic
needs in the fields of psychiatry and sleep medicine.
Product : Intermezzo- low dose zdpidem for middle of the night awakening
Partnering meeting 희망여부
49
Company name: 109 TVG LLC
Website: http://www.tvg-llc.com
Contact Person:Chicago USA [email protected]
Products and ServicesTechnology Vision Group LLC (TVG),
organizer of the 7th Annual BioPartnering Europe (BPE) conference for life
science companies, announces the extension of support available to delegates
Partnering meeting 희망여부
Company name: 110 University of Manitoba
Website: http://umanitoba.ca/
Contact Person: Winnipeg, MB R3E 0T6
Tel: (204) 789-3375 E-mail: [email protected]
Products and Services N/A
Partnering meeting 희망여부
Company name: 111 Vakzine Projekt Management GmbH (VPM)
Website: http://www.vakzine-manager.de
Contact Person:Hannover Germany
Tel.: +49 (0) 511 - 169 908-0
Products and ServicesA private vaccine and biopharmaceutical development company with a high
potential for value creation.
Pipeline : Phase II trial successfully completed:
VPM4001: allogeneic therapeutic Prostate Cancer vaccine based on irradiated
50
transfected LNCaP cells, producing IL-2 and IFN-y.
Preclinical projects: VPM5001 : Soluferon®, a second generation ß-interferon
for treatment for Multiple Sclerosis has a high potential to be developed for
treatment of viral infections
VPM1002: prophylactic Tuberculosis vaccine based on live recombinant M.
bovis BCG (rBCGΔureC-Hly) producing lysteriolysin for improved antigen
presentation
VPM2001: prophylactic vaccine against Human Cytomegalo Virus (HCMV)
using HCMV “dense bodies” as antigens
VPM1001: prophylactic Malaria vaccine based on adjuvanted full size MSP-1
(merozoite surface protein) from Plasmodium falciparum
Partnering meeting 희망여부
Company name: 112 Victory Pharma
Website: http:// www.victorypharma.com
Contact Person: [email protected] California USA
Products and ServicesVictory markets its pain management products to orthopedists,
rheumatologists, pain specialists and selected primary care physicians. At
Victory, our experienced sales representatives use their expert knowledge of
pain and related conditions as a resource to support healthcare professionals
in tailoring pain solutions to the needs of individual patients.
NAPRELAN, XODOL, FEXMID 7.5mg, DOLGIC Plus
Partnering meeting 희망여부
Company name: 113 VLST Corp
Website: http://www.vlstcorp.com
51
Contact Person: Ron Myers (Seattle USA)
VP Legal Affairs & Intellectual Property [email protected]
Products and ServicesProduct Candidates : VLST-007
VLST-007 addresses primary mechanisms of immune complexes and
macrophage/granulocyte activation that are not currently addressed by existing
therapeutics. Preclinical studies of VLST-007 have demonstrated the ability of
this therapeutic candidate to inhibit cytokine secretion from activated human
dendtiric cells. It has also shown positive effect on joint histopathology
compared to control.
The demonstration that VLST-007 can modulate immune-complex mediated
inflammation is significant because:
Potential clinical applications for VLST-007 include rheumatoid arthritis, SLE,
sjogren's syndrome, clomerulonephritis, vasculitides, cryoglobulenemia, ITP
and AIHA
Partnering meeting 희망여부
Company name: 114 Vyteris
Website: http://www.vyteris.com
Contact Person: [email protected] (NJ USA)
Products and ServicesProduct : LidoSite® – The first FDA-approved pre-filed active anesthetic
patch. Now available nation-wide in doctors’ offices, LidoSite® (Lidocaine
HCl/Epinephrine Topical Iontophoretic Patch) 10%/0.1% — Vyteris’
revolutionary active patch — provides fast, effective analgesia prior to blood
draws, venipunctures, and other superficial dermatological procedures.1,2 A
quick, noninvasive ten-minute application delivers lidocaine, a trusted
anesthetic, deep into the skin, significantly reducing the pain of needles.1,2
Partnering meeting 희망여부
Company name: 115 Washington Research Foundation
52
Website: http://www.wrfseattle.org
Contact Person:WRF Venture Center
Seattle, WA 98102 Tel: (206) 336-5600
Mr. Morgan Hellar
WRF Venture Center Manager [email protected]
Products and ServicesWashington Research Foundation (WRF) helps Washington State research
institutions capture value from their emerging technologies through intellectual
property management and start-up investment activities. From its licensing
successes, WRF built a seed venture fund, WRF Capital, to invest in local
private technology companies. WRF Capital's gains are used to support
research and entrepreneurship at Washington State research institutions.
The Washington Research Foundation negotiates license agreements with
interested companies capable of commercializing technologies emerging from
research institutions in Washington State
Partnering meeting 희망여부
Company name: 116 Welichem Biotech Inc.
Website: http://www.welichem.com/
Contact Person: [email protected] BC Canada
Products and ServicesProduct : Welichem's lead drug candidate, WBI-1001 , targets
autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A
phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis
has shown a very good safety profile and promising efficacy. As well,
Welichem plans to complete all the necessary Phase II Clinical Trials against
psoriasis and eczema in the near future. In our pipeline, WBI-1001 related
proprietary compounds are being evaluated also for their therapeutic potential
against other autoimmune diseases such as, inflammatory bowel disease and
rheumatoid arthritis.
WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours.
This is achieved in part through inhibition of angiogenesis and metastasis.
Animal tests have shown that WBI-2100 is effective as a monotherapy and
53
also in increasing the effectiveness of several commonly used
chemotherapeutic products.
On-going project : Atopic dermatitis, Psoriasis, cander, WBI-1001
autoimmune/inflammatory skin diseases, such as psoriasis and eczema.
Partnering meeting 희망여부
Company name: 117 Wolters Kluwer Health
Website: http://www.wkhealth.com
Contact Person: PA USA N/A
Products and Services A leading provider of information for professionals and students in medicine,
nursing, allied health, pharmacy and the pharmaceutical industry.
Professionals and students have long relied on our textbooks, reference
products, and journals. Wolters Kluwer Health’s bibliographic, reference and
pharmaceutical databases, drug information software, point-of-care tools, web-
based information systems and online continuing education products also
support the delivery of health information via interactive formats.
Partnering meeting 희망여부
Company name: 118 Xenome Ltd
Website: http://www.xenome.com/
Contact Person: Anthony Filippis - VP, Business Development (Australia)
email: [email protected]
ph: +61 7 3720 8055
Products and ServicesXenome is a biotechnology company focused on the discovery and
development of prptidu-based therapeutics.
Synthetic analogs of venom peptides are highly prospective for rapid drug
discovery and development, as their bioactive constituents have been
54
designed under selective pressure and perfected by evolution to be inherently
specific, potent and stable.
D iscovery platform : comprises a robust package of venom peptide
intellectual property, resources and expertise established to mine the
evolutionary advantages inherent in venom peptides and translate them into
therapeutic candidates.
Compound :Xenome has developed two key compound libraries to underpin
its discovery activities, xdiscover™ and xventure™ . Both libraries are novel
and proprietary, and are formatted for efficient target screening and SAR.
Partnering Interests : An essential component of Xenomecorporate strategy.
We are committed to identifying the best partners for our suite of products and
technologies.
Territorial/worldwide rights for the further development of Xen2174,
our lead product for severe pain, which is currently in Phase II clinical
trials
Accessing our unique, venom-based peptide libraries (xdiscover ™ and
xventure ™ ) for screening against therapeutic targets of interest
Out-licensing IND-ready peptide drug candidates
In addition, Xenome’s discovery and development capabilities are
underpinned by its expertise in peptide chemistry and its
understanding of the process for developing peptide drugs.
Partnering meeting 희망여부
Company name: 119 YM BioSciences Inc.
Website: http://www.ymbiosciences.com
Contact Person: [email protected]
Products and ServicesYM BioSciences is a therapeutic product development company that identifies
and advances a diverse portfolio of promising cancer-related products at
various stages of development.
55
Product: T wo late-stage products:
Nimotuzumab : an anti-cancer antibody in development in various
tumor types and approved in several major markets.
AeroLEF® : a proprietary, inhaled-delivery composition of fentanyl for
the treatment of moderate to severe acute pain.
http://www.ymbiosciences.com/products/index.php
Partnering meeting 희망여부
Company name: 120 Zymeworks
Website: http://zymeworks.com/
Contact Person: [email protected]
Products and ServicesZymeworks is a computational biotechnology company that combines
proprietary molecular simulation technology with high performance computing
to research and develop industrial enzymes and protein therapeutics
Zymeworks’ core business focus is to develop a pipeline of enabling enzymes
for the chemical industry and protein therapeutics for the pharmaceutical
industry
Partnering meeting 희망여부
56
![[제8회 국제자원순환산업전 참가기업 (Re-Tech 2015 Exhibitor] 톰라소팅㈜ / TOMRA Sorting](https://img.dokumen.tips/doc/110x75/55cfd641bb61ebf8188b459d/8-re-tech-2015-exhibitor-55d0cdcecd542.jpg)
![[제8회 국제자원순환산업전 참가기업 (Re-Tech 2015 Exhibitor)] 톰라소팅㈜ - 전기전자폐기물 적용방안](https://img.dokumen.tips/doc/110x75/55cfd533bb61ebd5558b483d/8-re-tech-2015-exhibitor-55d0cdd9b95db.jpg)
